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Objective: To establish evidence-based recommendations for the 
molecular analysis of lung cancers that are that are required to 
guide EGFR- and ALK-directed therapies, addressing which patients 
and samples should be tested, and when and how testing should be 
performed.
Participants: Three cochairs without conflicts of interest were selected, 
one from each of the 3 sponsoring professional societies: College of 
American Pathologists, International Association for the Study of Lung 
Cancer, and Association for Molecular Pathology. Writing and advisory 
panels were constituted from additional experts from these societies.
Evidence: Three unbiased literature searches of electronic databases 
were performed to capture articles published published from January 
2004 through February 2012, yielding 1533 articles whose abstracts were 
screened to identify 521 pertinent articles that were then reviewed in detail 
for their relevance to the recommendations. Evidence was formally graded 
for each recommendation.
Consensus Process: Initial recommendations were formulated by 
the cochairs and panel members at a public meeting. Each guideline 
section was assigned to at least 2 panelists. Drafts were circulated 
to the writing panel (version 1), advisory panel (version 2), and the 
public (version 3) before submission (version 4).
Conclusions: The 37 guideline items address 14 subjects, includ-
ing 15 recommendations (evidence grade A/B). The major rec-
ommendations are to use testing for EGFR mutations and ALK 
fusions to guide patient selection for therapy with an epidermal 
growth factor receptor (EGFR) or anaplastic lymphoma kinase 
(ALK) inhibitor, respectively, in all patients with advanced-stage 
adenocarcinoma, regardless of sex, race, smoking history, or other 
clinical risk factors, and to prioritize EGFR and ALK testing over 
other molecular predictive tests. As scientific discoveries and clin-
ical practice outpace the completion of randomized clinical trials, 
evidence-based guidelines developed by expert practitioners are 
vital for communicating emerging clinical standards. Already, 
new treatments targeting genetic alterations in other, less common 
driver oncogenes are being evaluated in lung cancer, and testing 
for these may be addressed in future versions of these guidelines.
(J Thorac Oncol. 2013;8: 823-859)
BACKGROUND—EGFR MUTATIONS 
AND ALK FUSIONS
Lung cancer is the leading cause of cancer-related mor-
tality, accounting for approximately 1.4 million deaths per 
year worldwide and approximately160 000 deaths per year in 
the United States, which is approximately 25% to 30% of all ISSN: 1556-0864/13/0807-0823
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US cancer deaths and more than the next 3 cancers (colon, 
prostate, breast) combined.1 Fortunately, the past decade has 
seen major advances in our understanding of the pathogenesis 
and management of lung cancers, adenocarcinoma in particu-
lar. Specifically, the discovery of the biologic and therapeu-
tic importance of acquired genetic alterations in 2 genes that 
encode pharmacologically targetable tyrosine kinases involved 
in growth factor receptor signaling, epidermal growth factor 
receptor (EGFR) and anaplastic lymphoma kinase (ALK), has 
changed the way these cancers are diagnosed and treated.
As gefitinib and erlotinib, small-molecule competitive 
inhibitors of the EGFR tyrosine kinase, were being evalu-
ated in clinical trials of advanced-stage lung cancer in the 
early part of the last decade, unusual prolonged responses to 
these medications were recognized in a subset of patients.2 
This unusual clinical behavior, not seen previously with 
standard chemotherapy, led to investigations that identified 
a correlation between activating somatic mutation in the 
EGFR gene and clinical response to gefitinib and erlotinib. 
This initial exciting observation has led to sustained and 
continuing laboratory and clinical investigations into the 
mechanism and clinical consequences of EGFR mutations 
in lung cancer. In unselected advanced non–small cell lung 
cancer (NSCLC) patients, gefitinib and erlotinib produce 
response rates of 8% to 9%, with a median time to progres-
sion of 2.2 months to 3.0 months.3 In contrast, advanced 
NSCLC patients selected on the basis of activating EGFR 
mutations in their tumors show response rates (RRs) of 
68%, with a mean progression-free survival (PFS) and time 
to progression of 12 months (Table 1).4–6
In 2009, the first randomized clinical trial (the Iressa 
Pan-Asia Study [IPASS]) showed that, for advanced NSCLC 
patients with an activating EGFR mutation, initial treatment 
with an EGFR tyrosine kinase inhibitor (TKI) was superior to 
standard platinum-based chemotherapy.7 In this study, which 
enrolled East Asian patients with stage IIIB/IV lung adenocar-
cinoma who never smoked tobacco (or only smoked lightly), 
the patients whose tumors contained an activating EGFR 
mutation and who received gefitinib had a significantly longer 
PFS than those receiving chemotherapy (hazard ratio [HR] for 
progression or death, 0.48; P <.001).7 Subsequently, 5 addi-
tional randomized controlled trials confirmed this association 
between activating EGFR mutations and objective response to 
gefitinib and/or erlotinib therapy (Table 2). However, in spite 
of these impressive differences in PFS, no study has shown 
an advantage in overall survival for EGFR-mutation–bearing 
patients treated initially with an EGFR TKI in comparison to 
chemotherapy. This is likely to be at least partly due to the 
crossover design of these studies, in that a large fraction of 
the patients with EGFR-mutated tumors treated initially with 
chemotherapy crossed over to the EGFR TKI treatment arm, 
confounding the interpretation of overall survival data.
Three years after the initial discoveries of EGFR muta-
tions in lung cancer, in 2007, Soda and coworkers8 reported 
TABle 1.  Different Outcomes in All Stages of Non–Small Cell Lung Cancer Patients With and Without EGFR Mutations, Treated 
With Tyrosine Kinase Inhibitor
Outcome
Mean ± SD Percentage
n (N) WMD (95% CI) RR (95% CI) P Value
EGFR 
Mutation 
Positive
EGFR 
Mutation 
Negative
EGFR 
Mutation 
Positive
EGFR 
Mutation 
Negative
Response rate, %a 68 11 51 (3644) 5.16 (4.41–6.04) <.001
Disease control rate, %b 86 42 28 (2204) 1.99 (1.73–2.29) <.001
Time to progression/progression-
free survival, moc
12.0 ± 7.86 3.4 ± 2.59 27 (2347) 8.66 (6.31–11.00) <.001
Median survival time, mod 23.3 ± 18.4 12.1 ± 13.9 27 (2489) 10.66 (8.36–12.96) <.001
Abbreviations: CI, confidence interval; n, number of studies; N, number of patients; RR, relative risk; SD, standard deviation; WMD, weighted mean difference.
aReferences 7, 17, 28, 48, 53, 56, 58, 110, 129, 133, 170, 191–198, 202, 211, 250–278.
bReferences 7, 17, 53, 56, 115, 129, 133, 191, 193–195, 202, 250–254, 258, 259, 261, 266, 267, 273–275, 277–279.
cReferences 17, 28, 53, 56, 58, 129, 170, 185, 191, 193, 195, 201, 211, 250–252, 254, 255, 261–263, 266, 267, 275–278.
dReferences 17, 28, 53, 56, 90, 129, 170, 183, 184, 191, 193, 197, 253–255, 258, 259, 261, 262, 266, 267, 270–272, 276–278.
TABle 2.  Randomized Clinical Trial Data on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy 
Versus Chemotherapy as First-Line Therapy for Patients With EGFR-Mutated Lung Cancers
Study No. of Patients With EGFR- 
Mutated Lung Cancers
Response Rate (EGFR TKI 
Versus Chemotherapy), %
Progression-Free Survival  
(EGFR TKI Versus Chemotherapy), mo
EURTAC280 173 (86 erlotinib and 87 chemo) 58 versus 15 9.7 versus 5.2 (HR 0.37)
OPTIMAL281 154 (82 erlotinib and 72 chemo) 83 versus 36 13.1 versus 4.6 (HR 0.16)
NEJ 00291 228 (114 gefitinib and 114 chemo) 74 versus 31 10.8 versus 5.4 (HR 0.30)
WJTOG340526 117 (58 gefitinib and 59 chemo) 62 versus 32 9.2 versus 6.3 (HR 0.49)
IPASS7,90 261 (132 gefitinib and 129 chemo) 71 versus 47 9.5 versus 6.3 (HR 0.48)
LUX LUNG3282 345 (230 afatinib and 115 chemo) 56 versus 23 11.1 versus 6.9 (HR 0.58)
Abbreviations: Chemo, chemotherapy; HR, hazard ratio.
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that an inversion on chromosome arm 2p resulted in the cre-
ation of an EML4-ALK fusion gene in lung cancer. The fusion 
gene was identified in 5 of 75 (7%) NSCLC patients exam-
ined. Subsequent studies have indicated that the prevalence of 
this gene fusion event is about 2% to 7% of all NSCLCs seen 
in the United States, with enrichment in adenocarcinomas in 
never smokers or light smokers.9–20 Testing for this ALK gene 
fusion has been facilitated by the commercial availability of 
a dual-probe “break-apart” fluorescence in situ hybridization 
(FISH) assay for ALK rearrangements that was already in clin-
ical use to detect ALK fusions in lymphomas and certain sar-
comas.15 A recent report of a large clinical series indicated that 
ALK rearrangements were seen in about 5% of 1500 NSCLC 
patients screened.13 Moreover, ALK rearrangement-positive 
patients treated with a novel ALK inhibitor, crizotinib, showed 
an overall response rate of 57%, with 72% having a PFS of 6 
months or greater.13 The US Food and Drug Administration 
(FDA) has approved crizotinib for advanced-stage, ALK-
positive lung cancer as is also recommended by recent guide-
lines from professional organizations, including the American 
Society of Clinical Oncology (ASCO), European Society 
for Medical Oncology, and National Comprehensive Cancer 
Network (NCCN).
Given the considerable published data on EGFR-
mutated lung cancer and the rapid pace of work on ALK, rep-
resentatives of 3 professional organizations with interest in the 
diagnosis and management of lung cancer—the College of 
American Pathologists (CAP), the International Association 
for the Study of Lung Cancer (IASLC), and the Association 
for Molecular Pathology (AMP)—convened to systematically 
review the published data and develop evidence-based recom-
mendations for the molecular testing of lung cancers for these 
2 critical predictive biomarkers in a clinical practice guideline 
(CPG).
CPGs are systematically developed statements intended 
to assist practitioners and patients in making decisions about 
appropriate health care options for specific clinical circum-
stances. Attributes of good CPGs include validity, reliability, 
reproducibility, clinical applicability, clinical flexibility, clar-
ity, multidisciplinary process, review of evidence, and docu-
mentation. Specifically, utilization of CPG recommendations 
may provide improvements in outcomes and in medical prac-
tice; minimize inappropriate practice variation; provide deci-
sion support tools for practitioners, a reference for medical 
education, criteria for self-evaluation, and indicators and crite-
ria for external quality review; and assist with reimbursement 
and coverage decisions. Finally, the process of CPG develop-
ment can also identify areas where further research is needed.
Clinical Practice Guideline Questions
This CPG addresses 5 principal and 14 corollary ques-
tions regarding molecular testing in NSCLC:
I. When should molecular testing for NSCLC be performed?
1. Which patients should be tested for EGFR mutations 
and ALK rearrangements?
2. When should a patient specimen be tested for EGFR
    mutations or ALK rearrangements?
3. How rapidly should test results be available?
II. How should EGFR testing be performed?
4. How should specimens be processed for EGFR muta-
tion testing?
5. What are the specimen requirements for EGFR test-
ing?
6. How should EGFR testing be performed?
7. What is the role of KRAS analysis in selecting pa-
tients for targeted therapy with EGFR TKIs?
8. What additional testing considerations are important 
in the setting of secondary or acquired EGFR TKI 
resistance?
III. How should ALK testing be performed?
9. What methods should be used for ALK testing?
IV. Should other genes be routinely tested in lung adenocar-
cinoma?
10. Are other molecular markers suitable for testing in 
lung cancer?
V. How should molecular testing of lung adenocarcinomas 
be implemented and operationalized?
11. Must all adenocarcinomas be tested for both EGFR 
and ALK?
12. How should EGFR and ALK results be reported?
13. How should EGFR and ALK testing be validated?
14. How should quality assurance be maintained?
Disclaimer
Clinical practice guidelines and consensus statements 
reflect the best available evidence and expert consensus sup-
ported in practice. They are intended to assist physicians and 
patients in clinical decision making and to identify questions 
and settings for further research. With the rapid flow of scien-
tific information, new evidence may emerge between the time 
a practice guideline or consensus statement is developed and 
when it is published or read. Guidelines and statements are 
not continually updated and may not reflect the most recent 
evidence. Guidelines and statements address only the topics 
specifically identified therein and are not applicable to other 
interventions, diseases, or stages of diseases. Furthermore, 
guidelines and statements cannot account for individual varia-
tion among patients and cannot be considered inclusive of all 
proper methods of care or exclusive of other treatments. It is 
the responsibility of the treating physician, relying on inde-
pendent experience and knowledge, to determine the best 
course of treatment for the patient. Accordingly, adherence 
to any practice guideline or consensus statement is voluntary, 
with the ultimate determination regarding its application to 
be made by the physician in light of each patient’s individual 
circumstances and preferences. CAP, IASLC, and AMP make 
no warranty, express or implied, regarding guidelines and 
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statements and specifically exclude any warranties of mer-
chantability and fitness for a particular use or purpose. CAP, 
IASLC, and AMP assume no responsibility for any injury or 
damage to persons or property arising out of or related to any 
use of this statement or for any errors or omissions.
In formulating recommendations for molecular testing 
in lung cancer, CAP, IASLC, and AMP considered these tenets 
of guideline development, emphasizing review of data from 
appropriately conducted and analyzed clinical trials. Practice 
guidelines are not intended to supplant physician judgment 
with respect to particular patients or special clinical situa-
tions. The literature and expert review process was directed 
toward evaluating and selecting the best science for the best 
possible patient care; a cost analysis was not performed for 
this guideline.
MeTHODS
A detailed account of the methods used to create this 
guideline can be found in the supplemental digital content at 
http://links.lww.com/JTO/A430.
Panel Composition
The CAP Pathology and Laboratory Quality Center, and 
representatives from the IASLC and AMP, jointly convened an 
expert author panel and scientific advisory panel consisting of 
experts in clinical pathology and oncology, and research and 
development relevant to molecular testing in NSCLC. A con-
ference with the expert author and advisory panels was held 
in December 2010, at which representatives from industry, 
public health policy and regulatory affairs, patient advocacy, 
and commercial drug and/or diagnostic device manufacturers 
were invited to participate. Representatives from the FDA, 
the National Cancer Institute, ASCO, and the NCCN attended 
the conference. The opinions of panel members associated 
with official government agencies represent their individual 
views and not necessarily those of the agency with which they 
are affiliated. All members of the expert (author) panel were 
required to disclose financial and personal conflicts of interest 
(see below).
Systematic literature Review and Analysis
The literature search strategy involved searching the 
following electronic databases from January 2004 through 
February 2012: Ovid MEDLINE, Ovid MEDLINE In-Process 
& Other Non-indexed Citations, and the Wiley Cochrane 
Library. The following keywords and MeSH terms were used 
in the search: lung neoplasms; lung cancer; carcinoma, non-
small-cell lung; EGFR; Epidermal growth factor receptor; 
ALK; KRAS; BRAF; mutation; amplification; gene copy num-
ber; rearrangement; fusion; translocation; inversion; immu-
nohistochemistry; IHC; and FISH. All searches were limited 
to the English language.
eligible Study Designs
Systematic reviews with or without meta-analyses, ran-
domized controlled trials, cohort studies, case-control stud-
ies, case series, and method comparisons were eligible for 
this study. Also included were testing guidelines and pro-
ficiency testing strategies of various US and international 
organizations.
Inclusion Criteria
Articles were eligible for inclusion if they met the fol-
lowing criteria:
1. The study compared, prospectively or retrospectively, the 
sensitivity, specificity, negative predictive value, or positive 
predictive value of EGFR or ALK tests for detection of an 
EGFR mutation, ALK rearrangement, or response to a tar-
geted EGFR or ALK TKI; the study described technical com-
parisons across various assay platforms; the study examined 
potential testing algorithms for NSCLC molecular testing; or 
the study examined the correlation of EGFR or ALK status in 
primary versus metastatic tumors from the same patients.
2. The study population consisted of patients with a diagno-
sis of NSCLC.
3. The primary outcomes included the sensitivity, specificity, 
positive predictive value, and negative predictive value 
of tests to determine EGFR or ALK status or treatment 
response, alone and in combination; concordance across 
platforms; and accuracy in determining EGFR or ALK sta-
tus and benefit from anti-EGFR or ALK TKI therapy.
exclusion Criteria
Letters, commentaries, editorials, reviews, and case 
reports were excluded.
Tests examined
Additional test methods considered included EGFR 
copy number by FISH or bright-field chromogenic in situ 
hybridization, immunohistochemistry for expression of 
ALK (kinase domain or carboxy-terminal) or mutated EGFR 
protein, and reverse transcription–polymerase chain reac-
tion (RT-PCR) detection of EML4-ALK fusion transcript. 
Alterations in other genes, including KRAS, BRAF, and MET, 
were also considered.
Outcomes of Interest
The primary outcomes of interest were the correlations 
between EGFR mutation or ALK rearrangement and benefit 
from EGFR or ALK TKI therapies, respectively. Other out-
comes of interest included accuracy in determining EGFR 
or ALK status, concordance across technical platforms, 
sensitivity, and specificity of different tests. After careful 
consideration of each of these, the expert panel and advi-
sory panel agreed that the primary recommendations of this 
guideline should focus on EGFR mutation assays and ALK 
FISH assays.
The panel reviewed the results of randomized controlled 
trials in lung cancer, evaluating therapies targeting EGFR or 
ALK, such as gefitinib, erlotinib, and crizotinib. The panel 
also reviewed unblinded trials comparing various testing 
methods, describing test characteristics, and defining strate-
gies for quality assurance of testing in the literature.
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environmental Scan
At the December 2010 conference, individuals repre-
senting regulatory agencies (FDA) also provided information 
about the regulatory framework. Individuals involved with 
quality assurance in the United States (CAP), the Netherlands, 
and Canada (Province of Ontario) also provided information 
about programs to measure and improve EGFR and ALK test-
ing. This information was used to help the panel specify test-
ing requirements and exclusions, and the necessary quality 
assurance monitoring that will make the testing less variable 
and more accurate.
Quality Assessment and Grading 
of the Included evidence
Grading of recommendations was based on overall 
ratings of individual components of the evidence, such as 
strength of evidence, its consistency, clinical impact, gen-
eralizability, and applicability to the international health 
care system.20–22 For strength of the evidence, we consid-
ered the level of evidence based on its hierarchy, number 
of studies and number of patients, magnitude of effect from 
the weighted mean difference or risk ratio, statistical pre-
cision measured as a point estimate or confidence interval, 
and methodologic quality of included studies.22 The quality 
of systematic reviews, randomized control trials, and cohort 
studies was assessed by using the AMSTAR (Assessment 
of Multiple Systematic Reviews) instrument and SIGN 
(Scottish Intercollegiate Guidelines Network) 50 checklists, 
respectively.23,24
The overall grade of the recommendation was obtained 
by rating all components of the evidence. The overall grade 
indicates the strength of the body of evidence to assist the 
users of clinical practice guidelines in making appropriate and 
informed clinical judgments.23 Grade A or B evidence sup-
ports “recommendations,” which are generally based on a 
body of evidence that can be trusted to guide clinical practice 
in all or in most situations. Grade C evidence is insufficient for 
a “recommendation” and provides support for “suggestions,” 
for which care should be taken in application. Grade D evi-
dence is weak and does not provide support for “recommen-
dations” or “suggestions.” Expert consensus opinion was used 
where grade C or above evidence was lacking.
Revision Dates
This guideline will be reviewed regularly, as mandated 
by publication of substantive and high-quality medical evi-
dence that could potentially alter the original guideline rec-
ommendations. If necessary, the entire panel will reconvene to 
discuss potential changes. When appropriate, panel members 
will recommend revision of the guideline to their respective 
organizations for review and approval.
Conflict of Interest Policy
Before acceptance on the expert panel, potential mem-
ber authors from all guideline partnering organizations com-
pleted the CAP conflict of interest process, whose policy and 
form requires disclosure of material financial interest in, or 
potential for benefit of significant value from, the guideline’s 
development or its recommendations beginning 12 months 
prior and ending when the guideline was submitted for pub-
lication (see “Appendix”). The potential members completed 
the conflict of interest disclosure form conservatively, listing 
any relationship that could be interpreted as constituting an 
actual, potential, or apparent conflict. Regarding members 
declaring potentially perceived or real conflict, guideline 
cochairs agreed that these individuals would best serve as 
advisory panel members for the guideline, but not authors on 
the expert panel. CAP, IASLC, and AMP provided funding 
for this project; no industry funds were used in the develop-
ment of the guideline.
OUTCOMeS
CAP/IASlC/AMP expert Panel literature 
Review and Analysis
The expert author panel cochairs (N.I.L, P.T.C., M.L.) 
reviewed 1533 potentially relevant abstracts identified in the 
original literature searches to select studies pertinent to the 
guideline: 2 cochairs independently reviewed each abstract, 
and disagreements were resolved by the third cochair. Full-
text articles (521) were then reviewed for all selected abstracts 
by 2 members of the expert author panel; discrepancies were 
resolved by a cochair. Evidence tables were developed from 
selected studies that met the criteria for inclusion. A third 
literature review was performed by the authors of each section 
of the guideline, to verify that the highest levels of evidence 
supported each of their recommendations and, if not, to 
reevaluate the recommendation and modify or defend it.
Consensus Development Based on evidence
The entire panel met in December 2010 (Chicago, 
Illinois); additional work on the guideline was completed 
through electronic mail and monthly teleconferences of the 
cochairs and/or expert panel. The purposes of the panel meet-
ing were to refine the questions addressed by the guideline, 
solicit input and testimony from the nonwriting advisory 
panel, and make writing assignments for the respective sec-
tions. All members of the expert panel participated in the 
preparation of the draft guideline, which was then dissemi-
nated for review by the entire panel. Feedback from external 
reviewers was also solicited. The content of the guideline and 
the manuscript were reviewed by an independent review panel 
and approved by the CAP Transformation Program Office 
Steering Committee, by the IASLC Board of Directors, and by 
the AMP Clinical Practice Committee and Executive Council. 
The recommendations are summarized in Table 3.
SeCTION I: WHeN SHOUlD MOleCUlAR 
TeSTING FOR NSClC Be PeRFORMeD?
Question 1: Which Patients Should Be Tested 
for EGFR Mutations and ALK Rearrangements?
1.1a:  Recommendation.—EGFR molecular testing 
should be used to select patients for EGFR-targeted 
TKI therapy, and patients with lung adenocarcinoma 
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TABle 3.  Summary of Guideline Recommendations
Section I: When Should Molecular Testing of Lung Cancers Be Performed?
 Question 1: Which Patients Should Be Tested for EGFR Mutations and ALK Rearrangements?
  1.1a:  Recommendation: EGFR molecular testing should be used to select patients for EGFR- targeted TKI therapy, and patients with lung adenocarcinoma 
should not be excluded from testing on the basis of clinical characteristics.
  1.1b:  Recommendation: ALK molecular testing should be used to select patients for ALK-targeted TKI therapy, and patients with lung adenocarcinoma 
should not be excluded from testing on the basis of clinical characteristics.
  1.2:  Recommendation: In the setting of lung cancer resection specimens, EGFR and ALK testing is recommended for adenocarcinomas and mixed 
lung cancers with an adenocarcinoma component, regardless of histologic grade. In the setting of fully excised lung cancer specimens, EGFR and 
ALK testing is not recommended in lung cancers that lack any adenocarcinoma component, such as pure squamous cell carcinomas, pure small cell 
carcinomas, or large cell carcinomas lacking any immunohistochemistry (IHC) evidence of adenocarcinoma differentiation.
  1.3:  Recommendation: In the setting of more limited lung cancer specimens (biopsies, cytology) where an adenocarcinoma component cannot be 
completely excluded, EGFR and ALK testing may be performed in cases showing squamous or small cell histology but clinical criteria (eg, young 
age, lack of smoking history) may be useful in selecting a subset of these samples for testing.
  1.4:  Recommendation: To determine EGFR and ALK status for initial treatment selection, primary tumors or metastatic lesions are equally suitable for 
testing.
  1.5:  Expert consensus opinion: For patients with multiple, apparently separate, primary lung adenocarcinomas, each tumor may be tested but testing of 
multiple different areas within a single tumor is not necessary.
 Question 2: When Should a Patient Specimen Be Tested for EGFR Mutation or ALK Rearrangement?
  2.1a:  Recommendation: EGFR mutation testing should be ordered at the time of diagnosis for patients presenting with advanced-stage disease (stage IV 
according to the 7th edition TNM staging system) who are suitable for therapy or at time of recurrence or progression in patients who originally 
presented with lower-stage disease but were not previously tested.
  2.1b:  Suggestion: ALK rearrangement testing should be ordered at the time of diagnosis for patients presenting with advanced-stage disease (stage IV 
according to the 7th edition TNM staging system) who are suitable for therapy or at time of recurrence or progression in patients who originally 
presented with lower-stage disease but were not previously tested.
  2.2a:  Expert consensus opinion: EGFR testing of tumors at diagnosis from patients presenting with stage I, II, or III disease is encouraged but the decision 
to do so should be made locally by each laboratory, in collaboration with its oncology team.
  2.2b:  Expert consensus opinion: ALK testing of tumors at diagnosis from patients presenting with stage I, II, or III disease is encouraged, but the decision 
to do so should be made locally by each laboratory, in collaboration with its oncology team.
  2.3:  Recommendation: Tissue should be prioritized for EGFR and ALK testing.
 Question 3: How Rapidly Should Test Results Be Available?
  3.1:  Expert consensus opinion: EGFR and ALK results should be available within 2 weeks (10 working days) of receiving the specimen in the testing 
laboratory.
  3.2:  Expert consensus opinion: Laboratories with average turnaround times beyond 2 weeks need to make available a more rapid test—either in-house or 
through a reference laboratory—in instances of clinical urgency.
  3.3:  Expert consensus opinion: Laboratory departments should establish processes to ensure that specimens that have a final histopathologic diagnosis 
are sent to outside molecular pathology laboratories within 3 working days of receiving requests and to intramural molecular pathology laboratories 
within 24 hours.
Section II: How Should EGFR Testing Be Performed?
 Question 4: How Should Specimens Be Processed for EGFR Mutation Testing?
  4.1:  Expert consensus opinion: Pathologists should use formalin-fixed, paraffin-embedded (FFPE) specimens or fresh, frozen, or alcohol-fixed specimens 
for PCR-based EGFR mutation tests. Other tissue treatments (eg, acidic or heavy metal fixatives, or decalcifying solutions) should be avoided in 
specimens destined for EGFR testing.
  4.2: Expert consensus opinion: Cytologic samples are also suitable for EGFR and ALK testing, with cell blocks being preferred over smear preparations.
 Question 5: What Are the Specimen Requirements for EGFR Testing?
  5.1: Expert consensus opinion: Pathologists should determine the adequacy of specimens for EGFR testing by assessing cancer cell content and DNA 
quantity and quality.
  5.2:  Expert consensus opinion: Each laboratory should establish the minimum proportion and number of cancer cells needed for mutation detection 
during validation.
  5.3:  Expert consensus opinion: A pathologist should assess the tumor content of each specimen and either perform, or guide a trained technologist to 
perform, microdissection for tumor cell enrichment as needed.
 Question 6: How Should EGFR Testing Be Performed?
  6.1: Recommendation: Laboratories may use any validated EGFR testing method with sufficient performance characteristics.
  6.2:  Expert consensus opinion: Laboratories should use EGFR test methods that are able to detect mutations in specimens with at least 50% cancer cell 
content, although laboratories are strongly encouraged to use (or have available at an external reference laboratory) more sensitive tests that are able 
to detect mutations in specimens with as little as 10% cancer cells.
  6.3:  Expert consensus opinion: Clinical EGFR mutation testing should be able to detect all individual mutations that have been reported with a frequency 
of at least 1% of EGFR-mutated lung adenocarcinomas.
  6.4: Recommendation: Immunohistochemistry for total EGFR is not recommended for selection of EGFR TKI therapy.
  6.5: Recommendation: EGFR copy number analysis (ie, FISH or CISH) is not recommended for selection of EGFR TKI therapy.
(Continued)
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should not be excluded from testing on the basis of 
clinical characteristics.
1.1b:  Recommendation.—ALK molecular testing should 
be used to select patients for ALK-targeted TKI 
therapy, and patients with lung adenocarcinoma 
should not be excluded from testing on the basis of 
clinical characteristics.
Evidence Grade: EGFR: A; ALK: B.—Clinical charac-
teristics (eg, age, sex, ethnicity, smoking history) are not suf-
ficiently sensitive or specific to be used to select or exclude 
patients for treatment or testing. Ethnicity, smoking history, 
and sex have all been associated with the presence of EGFR 
mutations in NSCLC. Multiple studies have established that 
EGFR mutations are more common in women than men, in 
patients who have never smoked tobacco than in patients who 
have smoked tobacco, and in East Asians than in other ethnic 
groups.7,25–29 In contrast to EGFR-mutated lung cancer, ALK 
gene fusions do not show sharp differences in prevalence 
according to sex and ethnic origin, but do show a similar 
strong association with patients who have never smoked 
tobacco and younger age.11,18,30,31 However, while these clinical 
characteristics may have value for population studies, they are 
insufficiently specific to be used to select individual patients 
for treatment with a targeted inhibitor. Similarly, these charac-
teristics are insufficiently sensitive to be used as prerequisites 
for testing an individual patient for EGFR mutation or ALK 
fusion, as significant numbers of patients who might benefit 
from EGFR- or ALK-targeted therapy might be inappropri-
ately excluded (Tables 4 through 7). Prediction models com-
bining several of these variables to define patients who have a 
very low probability of EGFR mutations (eg, <1%) have been 
developed but will require further evaluation.32,33
1.2:  Recommendation.—In the setting of lung cancer 
resection specimens, EGFR and ALK testing is 
recommended for adenocarcinomas and mixed lung 
TABle 3.  Continued
 Question 7: What Is the Role of KRAS Analysis in Selecting Patients for Targeted Therapy With EGFR TKIs?
  7.1: Recommendation: KRAS mutation testing is not recommended as a sole determinant of EGFR TKI therapy.
 Question 8: What Additional Testing Considerations Are Important in the Setting of Secondary or Acquired EGFR TKI Resistance?
  8.1:  Recommendation: If a laboratory performs testing on specimens from patients with acquired resistance to EGFR kinase inhibitors, such tests should 
be able to detect the secondary EGFR T790M mutation in as few as 5% of cells.
Section III: How Should ALK Testing Be Performed?
 Question 9: What Methods Should be Used for ALK testing?
  9.1:  Recommendation: Laboratories should use an ALK FISH assay using dual-labeled break-apart probes for selecting patients for ALK TKI therapy; 
ALK immunohistochemistry, if carefully validated, may be considered as a screening methodology to select specimens for ALK FISH testing.
  9.2: Recommendation: RT-PCR is not recommended as an alternative to FISH for selecting patients for ALK inhibitor therapy.
  9.3:  Expert consensus opinion: A pathologist should be involved in the selection of sections for ALK FISH testing, by assessing tumor architecture, 
cytology, and specimen quality.
  9.4:  Expert consensus opinion: A pathologist should participate in the interpretation of ALK FISH slides, either by performing the analysis directly or by 
reviewing the interpretations of cytogeneticists or technologists with specialized training in solid tumor FISH analysis.
  9.5:  Expert consensus opinion: Testing for secondary mutations in ALK associated with acquired resistance to ALK inhibitors is not currently required for 
clinical management.
Section IV: Should Other Genes Be Routinely Tested in Lung Adenocarcinoma?
 Question 10: Are Other Molecular Markers Suitable for Testing in Lung Cancer?
  10.1a: Recommendation: Testing for EGFR should be prioritized over other molecular markers in lung adenocarcinoma.
  10.1b:  Suggestion: After EGFR testing, testing for ALK should be prioritized over other proposed molecular markers in lung adenocarcinoma, for which 
published evidence is insufficient to support testing guideline development at the present time.
Section V: How Should Molecular Testing of Lung Adenocarcinomas Be Implemented and Operationalized?
 Question 11: Must All Adenocarcinomas Be Tested for Both EGFR and ALK?
  11.1:  Expert consensus opinion: Laboratories may implement testing algorithms to enhance the efficiency of molecular testing of lung adenocarcinomas, 
provided the overall turnaround time requirements are met.
 Question 12: How Should EGFR and ALK Results Be Reported?
  12.1:  Expert consensus opinion: EGFR mutation testing reports and ALK FISH reports should include a results and interpretation section readily 
understandable by oncologists and by nonspecialist pathologists.
 Question 13: How Should EGFR and ALK Testing Be Validated?
  13.1: Expert consensus opinion: EGFR and ALK testing validation should follow the same guidelines as for other molecular diagnostics and FISH tests.
 Question 14: How Should Quality Assurance Be Maintained?
  14.1:  Expert consensus opinion: Laboratories should follow similar quality control and quality assurance policies and procedures for EGFR and ALK 
testing in lung cancers as for other clinical laboratory assays. In particular, laboratories performing EGFR and ALK testing for TKI therapy should 
enroll in proficiency testing, if available.
Abbreviations: CISH, chromogenic in situ hybridization; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; PCR, polymerase chain reaction; RT-
PCR, reverse transcription–polymerase chain reaction; TKI, tyrosine kinase inhibitor; TNM, tumor, node, metastasis.
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cancers with an adenocarcinoma component, regard-
less of histologic grade. In the setting of fully excised 
lung cancer specimens, EGFR and ALK testing is not 
recommended in lung cancers that lack any adeno-
carcinoma component, such as “pure” squamous cell 
carcinomas, “pure” small cell carcinomas, or large 
cell carcinomas lacking any immunohistochemistry 
(IHC) evidence of adenocarcinoma differentiation.
Evidence Grade: EGFR and ALK: A.—As a pream-
ble to the discussion of this recommendation, we note that 
“non–small cell” lung carcinoma is no longer considered 
appropriate as a pathologic diagnosis for resection speci-
mens or as an operational category for clinical management. 
This evolution is also reflected in the version 3.2012 NCCN 
guidelines that recommend avoiding use of the generic 
term non–small cell lung carcinoma (NSCLC) as a single 
diagnostic term for complete resection specimens.34 The 
distinction between squamous carcinoma, small cell car-
cinoma, neuroendocrine carcinoma, and adenocarcinomas 
has become critical for determining subsequent molecular 
characterization of tumors and patient management.
EGFR mutations have been detected in several histo-
logic lung cancer types, but most tumors with EGFR mutations 
are adenocarcinomas or mixed carcinomas with an adenocar-
cinoma component, including adenosquamous carcinomas. 
While there is some evidence that EGFR mutations are more 
likely in low-grade adenocarcinomas with lepidic, papillary, 
or acinar histology than in poorly differentiated, mucinous, or 
solid adenocarcinomas, EGFR mutations are found at signifi-
cant frequencies in adenocarcinomas of all grades. Therefore, 
adenocarcinoma subtype should not be used as a determinant 
of which samples should, or should not, be tested.35–38
ALK rearrangements are also associated with adenocar-
cinoma histology, without any single subtype being strongly 
predictive. Studies in Western populations have shown that 
ALK rearrangements are more frequent in adenocarcinomas 
with largely solid histology and/or signet ring cells, but this 
has not been observed in East Asian populations.17,39,40 ALK 
fusions appear very infrequent in squamous cell carcinomas 
lacking any adenocarcinoma component (Table 8) but have 
been reported in adenosquamous carcinomas.41
Likewise, EGFR mutations are very infrequent in well-
characterized fully excised specimens of squamous cell carci-
noma lacking any adenocarcinoma component.35,38,42–51 A few 
studies52–60 have reported EGFR mutations in squamous cell 
carcinoma at a low frequency (Table 9). Most of these lat-
ter studies have focused on molecular or clinical data from 
patients with advanced disease diagnosed by small biopsies, 
TABle 5.  Clinicopathologic Characteristics in Relation to 
EGFR Mutation Status in Studies Containing Primarily Asian 
Patientsa
EGFR 
Mutation 
Prevalence, 
%
EGFR 
Mutation 
Positive
EGFR 
Mutation 
Negative n (N)
Age with cutoff, y
 <65b 46 370 433 6 (803)
 ≥65c 38 432 709 5 (1141)
Sex
 Femaled 58 1027 733 27 (1760)
 Malee 32 456 962 26 (1418)
Smoking
 Neverf 58 843 599 22 (1442)
 Everf 26 265 767 22 (1032)
History of smoking, pack-years
 0–10g 67 10 5 1 (15)
 11–40g 45 5 6 1 (11)
 >40g 23 5 17 1 (22)
 >20h 25 13 40 1 (53)
Histology
 Adenocarcinomai 50 1278 1256 25 (2534)
 Squamousj 5 8 160 8 (168)
 Adenosquamousk 67 4 2 2 (6)
 Large celll 7 1 14 4 (15)
Differentiation
 Two grades
  Wellm 37 62 107 3 (169)
  Moderate to poorm 14 27 162 3 (189)
 Three grades
  Welln 65 28 15 2 (43)
  Moderaten 48 59 63 2(122)
  Poorn 34 17 33 2 (50)
Abbreviations: n, number of studies; N, number of patients.
aMost studies contained primarily patients with adenocarcinoma.
bReferences 7, 55, 184, 272, 276, 290.
cReferences 55, 184, 272, 276, 290.
dReferences 7, 32, 35, 48, 49, 55, 133, 184, 185, 257, 264, 269, 270, 272, 274–276, 278, 283–287, 289–291, 296.
eReferences 32, 35, 48, 49, 55, 133, 184, 185, 257, 264, 269, 270, 272, 274–276, 278, 283–287, 289–291, 296.
fReferences 32, 35, 55, 133, 184, 185, 257, 264, 269, 270, 274–276, 278, 283–285, 287, 289–291, 296.
gReference 290.
hReference 272.
iReferences 32, 35, 48, 49, 55, 133, 184, 185, 257, 264, 269, 270, 272, 274–276, 278, 283–286, 289–291, 296.
jReferences 55, 257, 264, 272, 274, 275, 289, 296.
kReferences 272, 289.
lReferences 48, 272, 275, 289.
mReferences 119, 184, 202.
nReferences 49, 184.
TABle 4. EGFR Mutation Prevalence in Different Lung 
Adenocarcinoma Patient Populationsa
EGFR Mutation 
Prevalence, %
EGFR 
Mutation 
Positive
EGFR 
Mutation 
Negative n (N)
Asian/Pacificb 45 1547 1905 31 (3452)
Whitec 24 853 2681 10 (3534)
African Americand 20 19 78 3 (97)
Hispanice 17 65 307 4 (372)
Asian/Indianf 52 114 106 1 (220)
Abbreviations: n, number of studies; N, number of patients.
aData for other populations were absent or too limited for analysis.
bReferences 7, 17, 32, 35, 48, 49, 55, 133, 184, 185, 191, 257, 264, 269, 270, 272–276, 278, 283–292.
cReferences 17, 32, 191, 192, 253, 273, 288, 292–294.
dReferences 256, 288, 293.
eReferences 128, 254, 267, 288.
fReference 295.
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raising concerns that many, if not most, of these EGFR-
mutated “squamous” cancers may have been small biopsies 
in which the diagnosis of adenosquamous or poorly differenti-
ated adenocarcinomas can be challenging.35,40 As this histo-
logic distinction is becoming critical in the selection of cases 
for mutation analysis, in cases where the distinction between 
poorly differentiated squamous cell carcinoma and poorly dif-
ferentiated adenocarcinoma is especially difficult, appropriate 
IHC should be performed for TTF-1, P63, or P40, and other 
relevant markers.61–63 Likewise, undifferentiated or large cell 
carcinomas with histochemical or immunohistochemical evi-
dence of adenocarcinoma lineage (eg, TTF-1 or mucin posi-
tive) or lacking IHC evidence of squamous carcinoma lineage 
(eg, p63 or p40 negative) are also appropriate for EGFR and 
ALK testing. The use of IHC and other specialized histochem-
ical techniques to establish lineage in lung adenocarcinoma is 
an evolving field (and the selection of stains/antibodies and 
their associated interpretive criteria) and is outside the scope 
of this guideline. The interested reader is referred to published 
IASLC guidelines for an introduction to this topic.63
EGFR mutations have not been detected in small cell 
lung cancer (SCLC), except in rare cases of combined SCLC 
with an adenocarcinoma component; in some of these cases a 
response to EGFR TKI was reported.64–69 In addition, adeno-
carcinomas with EGFR mutations that were initially treated 
successfully with an EGFR TKI may show transformation to 
small cell histology at relapse, as a mechanism of resistance; 
in these patients, the recurrence of the lung cancer as a small 
cell carcinoma retains the EGFR mutation from the anteced-
ent adenocarcinoma.69–71
Among other subtypes of lung cancer, rare EGFR 
mutations have been reported in pulmonary salivary gland–
type tumors, large cell carcinomas, sarcomatoid carcinomas, 
and large cell neuroendocrine carcinoma.34,72–77 This guide-
line does not make specific recommendations for these less 
common tumors, although testing of large cell carcinomas 
showing IHC evidence of adenocarcinoma differentiation 
should be considered.77 EGFR mutations have not been found 
in carcinoids.78
1.3:  Recommendation.—In the setting of more limited 
lung cancer specimens (biopsies, cytology) where an 
adenocarcinoma component cannot be completely 
excluded, EGFR and ALK testing may be performed 
in cases showing squamous or small cell histology 
but clinical criteria (eg, young age, lack of smoking 
history) may be useful in selecting a subset of these 
samples for testing.
Evidence Grade: EGFR and ALK: A.—Lung cancers 
with mixed histology (eg, adenosquamous, mixed adeno/small 
cell) can have mutations in EGFR or rearrangements in ALK 
and, if so, respond to treatment.79 Therefore, in tissues with 
incomplete sampling in which the possibility of an adenocar-
cinoma component cannot be excluded, testing may be indi-
cated. In this context, clinical criteria, such as young age, lack 
of smoking history, or a documented preceding adenocarci-
noma, may be used to select patients for testing.
1.4:  Recommendation.—To determine EGFR and ALK 
status for initial treatment selection, primary tumors 
or metastatic lesions are equally suitable for testing.
Evidence Grade: EGFR and ALK: B.—Discordances 
in EGFR mutation status between primary tumors and cor-
responding metastases appear rare80 (Table 10). The clini-
cal significance of these relatively uncommon discrepancies 
remains uncertain but it should be noted that some discrep-
ancies may reflect the higher risk of false negatives when 
analyzing lung cancer metastatic to lymph nodes due to the 
admixture of lymphoid cells. Accordingly, the choice of 
which sample to test should be based primarily on the speci-
men qualities themselves (tumor content and preservation), 
rather than whether they are primary or metastatic lesions. 
All things being equal, the most recent available tissue is 
preferred, but no evidence supports subjecting a patient to a 
procedure to procure tissue specifically to obtain testing of 
a metastasis before initiation of TKI therapy when an earlier 
primary lesion is available and suitable for analysis, unless 
there is a strong clinical suspicion of its origin from a sepa-
rate primary tumor.
This is in contrast to patients with metastasis or 
relapse after initially successful response to TKI treatment 
(ie, acquired resistance), in which case repeated biopsies are 
performed to confirm a clonal relationship to the treated pri-
mary tumor, permit analysis of the mechanism of resistance 
TABle 6.  Clinicopathologic Characteristics in Relation to 
EGFR Mutation Status in Studies Containing Primarily Non-
Asian Patientsa
EGFR 
Mutation 
Prevalence, %
EGFR 
Mutation 
Positive
EGFR 
Mutation 
Negative n (N)
Sex
 Femaleb 28 859 2239 19 (3098)
 Maleb 18 397 1768 19 (2165)
Smoking
 Neverc 45 666 805 18 (1471)
 Everc 15 569 3154 18 (3723)
History of smoking, pack-years
 0–10d 39 18 28 1 (46)
 11–50d 8 7 86 1 (93)
 >50d 5 3 56 1 (59)
Histology
 Adenocarcinomae 24 1266 3918 19 (5184)
 Squamousf 5 6 104 9 (110)
 Adenosquamousg 13 1 7 2 (8)
 Large cellh 5 2 37 6 (39)
Abbreviations: n, number of studies; N, number of patients.
aMost studies contained primarily patients with adenocarcinoma.
bReferences 17, 32, 87, 115, 128, 191–193, 253, 254, 256, 267, 273, 288, 292–295, 297.
cReferences 17, 32, 87, 128, 191–193, 253, 254, 256, 267, 273, 288, 292–295, 297.
dReference 288.
eReferences 17, 32, 87, 115, 128, 191–193, 253, 254, 256, 267, 273, 288, 292–294, 297, 298.
fReferences 17, 191, 193, 254, 256, 267, 273, 288, 298.
gReferences 17, 288.
hReferences 17, 193, 254, 267, 273, 298.
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and, potentially, direct the patient to targeted, protocol-based 
experimental therapies that may differ according to the mech-
anism of acquired resistance.
1.5:  Expert Consensus Opinion.—For patients with mul-
tiple, apparently separate, primary lung adenocarcino-
mas, each tumor may be tested but testing of multiple 
different areas within a single tumor is not necessary.
Separate primary tumors that harbor different muta-
tions are not uncommon.81 If an EGFR mutation is discov-
ered in any tumor, the patient may benefit from an EGFR 
TKI. Therefore, if a patient presents with apparently sepa-
rate primary tumors (based on location and nonoverlapping 
histologic features), each primary tumor may be tested. 
However, the decision whether or not to test each of a 
patient’s multiple tumors depends on each patient’s clinical 
context and requires communication between the laboratory 
and the clinical care team.
Adequate evidence has not been published to support 
mutation analysis of different regions of a tumor, neither with 
respect to mutation sensitivity in otherwise sufficiently cel-
lular regions, nor with respect to clinical outcomes. Although 
some data suggest that variation in EGFR copy number within 
a tumor may impact mutation detection rate in samples from 
different zones of the tumor, performing FISH to select an 
area for mutation testing is impractical, and any area with 
sufficient tumor content to enable detection of a mutation 
may be selected for analysis.80,82–84 Recent detailed genomic 
studies in other cancers have provided further support for the 
concept that key driver mutations are well preserved but sec-
ondary mutations are not.85 As key driver mutations, EGFR 
mutations and ALK fusions appear to follow this pattern and 
this is further supported by the extreme rarity of the EGFR 
wild-type recurrent tumors in patients with EGFR-mutated 
lung adenocarcinomas treated with EGFR TKIs.70
Question 2: When Should a Patient 
Specimen Be Tested for EGFR 
Mutation or ALK Rearrangement?
2.1a:  Recommendation.—EGFR mutation testing should 
be ordered at the time of diagnosis for patients 
TABle 7.  Clinicopathologic Characteristics in Relation to ALK Rearrangement Statusa
ALK Rearrangement 
Prevalence, %
ALK Rearrangement 
Positive
ALK Rearrangement 
Negative
n (N)
Age with cutoff, y
 ≤6520 6 13 210 1 (223)
 >6520 3 6 224 1 (230)
Sex
 Females11,12,15,20 5 28 579 4 (607)
 Males11,12,15,20 4 30 738 4 (768)
Smoking
 Never11,15,20 8 30 331 3 (361)
 Ever11,15,20 3 20 652 3 (672)
Ethnicity
 Asian/Pacific11,12,14 5 35 654 3 (689)
 White (Caucasian)12,15 4 22 474 2 (496)
Histology
 Adenocarcinoma9,11,12,15,16,19,20 5 67 1319 7 (1386)
 Squamous9,11,12,16,19,20 0.2 1 522 6 (523)
 Adenosquamous11,12,19 0 0 19 3 (19)
Differentiation
 Well11 1 1 97 1 (98)
 Not well11 6 10 145 1 (155)
Abbreviations: n, number of studies; N, number of patients.
aMost studies contained primarily patients with adenocarcinoma.
TABle 8.  Studies Specifically Reporting Outcome of ALK 
Rearrangement Studies in Squamous Cell Carcinomas
Source, y n
ALK Rearrangement 
Positive, %
Takeuchi et al,299 2008 71 0
Takahashi et al,39 2010 75 0
Inamura et al,10 2008 48 0
Abbreviation: n, number of squamous cell carcinoma samples tested.
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presenting with advanced-stage disease (stage IV 
according to the 7th edition tumor node metastasis 
[TNM] staging system) who are suitable for therapy, 
or at time of recurrence or progression in patients 
who originally presented with lower-stage disease 
but were not previously tested.
2.1b:  Suggestion.—ALK rearrangement testing should be 
ordered at the time of diagnosis for patients present-
ing with advanced-stage disease (stage IV according 
to the 7th edition TNM staging system) who are 
suitable for therapy, or at time of recurrence or pro-
gression in patients who originally presented with 
lower-stage disease but were not previously tested.
Evidence Grade: EGFR: A; ALK: C.—Patients with 
advanced-stage disease have short life expectancies, on 
the order of 4 to 5 months in the absence of treatment. 
Although patients may derive some benefit from first-line 
chemotherapy with use of targeted TKIs as second-line 
agents, patients with EGFR mutations/ALK rearrangements 
show superior outcomes when the targeted TKI therapies 
are administered as first-line agents.34,86 For these patients, 
timely diagnosis is critical and molecular testing should 
be initiated as soon as a diagnosis of adenocarcinoma is 
established.
Reflex testing, a testing policy that does not require 
a separate clinician order for each case, is appropriate if 
agreed upon by the lung cancer care team and may help to 
ensure expedited and consistent routing of specimens for 
molecular testing. However, some patients may not be can-
didates for targeted TKI therapy for clinical reasons, and 
good communication between the clinical care team and the 
testing laboratory is needed to ensure testing is performed 
for patients whose management will be impacted by the test 
result. Specifically, testing is not necessary for patients with 
stage IV disease who are being considered for palliative or 
hospice care only. Similarly, in settings in which reflex test-
ing is the practice, a mechanism should be provided for the 
clinical care team to communicate to the pathologist exam-
ining a small biopsy or cytology sample when a more suit-
able diagnostic specimen (eg, a resection) is expected to be 
obtained, and the molecular testing should be deferred to 
the subsequent, more generous sample.
2.2a:  Expert Consensus Opinion.—EGFR testing of 
tumors at diagnosis from patients presenting with 
stage I, II, or III disease is encouraged but the deci-
sion to do so should be made locally by each labora-
tory, in collaboration with its oncology team.
2.2b:  Expert Consensus Opinion.—ALK testing of 
tumors at diagnosis from patients presenting with 
stage I, II, or III disease is encouraged, but the deci-
sion to do so should be made locally by each labora-
tory, in collaboration with its oncology team.
Patients with localized disease have a potential for sur-
gical cure and may never need targeted therapies. Testing the 
initial surgical specimen at the time of resection affords the 
benefits of having recent tissue to test as well as, in many 
instances, larger resection specimens with ample material. 
By contrast, excluding patients with early-stage disease from 
testing and waiting until progression may necessitate testing 
of a smaller biopsy sample of borderline quality or quantity 
and/or subjecting patients to invasive procedures in order 
to obtain adequate samples, or trying to retrieve the earlier 
resection specimen from long-term storage or from another 
TABle 9.  Major Studies Specifically Reporting EGFR Mutation Analysis in Surgically Resected Squamous Cell Carcinomas as 
Compared to Adenocarcinomas
Source, y
Predominant Ethnic Origin of 
Study Population
EGFR Mutations in Resected 
Adenocarcinomas, No. (%)
EGFR Mutations in Resected  
Squamous Cell Carcinomas, No. (%)
Marchetti et al,45 2005 European 39/375 (10.4) 0/454
Sugio et al,43 2006 Asian 136/322 (42.2) 0/102
Tsao et al,44 2006 North American 14/96 (14.6) 0/63
Tsao et al,60 2011 North American 32/231 (13.9) 8/162 (4.9)
Bae et al,284 2007 Asian 20/55 (36.4) 0/60
Lee et al,300 2010 Asian 36/117 (30.8) 0/56
Miyamae et al,301 2011 Asian … 3/87a (3.4)
Rekhtman et al,36 2012 North American … 0/95
TCGA,302,b 2012 North American … 2/178c (1.1)
aThese numbers do not include 2 EGFR-mutated cases reclassified as adenocarcinoma and adenosquamous carcinoma on the basis of immunohistochemistry (IHC) for thyroid 
transcription factor 1 (TTF-1)/p63; the remaining 3 EGFR-mutated cases were reported as IHC-confirmed squamous cell carcinoma.
bThe Cancer Genome Atlas Research Network.
cBoth EGFR mutations were L861R.
TABle 10.  Summary of Studies of the Concordance of EGFR 
Mutations in Primary Versus Metastatic Tumors in the Same 
Patienta
Metastatic Lesions
Primary Tumor
EGFR+ EGFR−
EGFR+ 108 6
EGFR− 11 183
aData derived from Park et al57; Yatabe et al80; and Sun et al.303
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institution, which can be challenging and time-consuming. 
Furthermore, EGFR testing may have use as a favorable prog-
nostic factor, beyond its use as a predictor of response to tar-
geted inhibitors.86,87
These benefits of testing all early-stage disease patients 
must be balanced against the cost of performing testing that 
may not be used to select therapy for the patients who never 
have relapse. The portability of the initial testing results 
should also be considered, in the case of a patient with a 
delayed relapse who may present for targeted therapy years 
later at another institution.
Currently, the question of whether or not to test a diag-
nostic specimen in early-stage disease is a local decision that 
must be made in conjunction with each institution’s oncology 
care team, as insufficient published evidence supports a uni-
versal recommendation. However, evidence to support this 
treatment practice may be forthcoming. Traditionally, most 
novel therapeutic agents are studied initially in patients with 
advanced disease that is refractory to standard therapy. If 
activity is noted in this setting, the agents are typically next 
studied in the first-line setting for advanced-stage disease. If 
activity is noted in this setting, then the agent may be stud-
ied in earlier-stage disease. This is where EGFR inhibitors 
are today—given the success in first-line treatment of patients 
with advanced-stage disease and EGFR mutations, a next 
wave of clinical trials will test whether these agents may be 
beneficial as adjuvant therapy in early-stage disease, a notion 
already supported by retrospective analyses.88 ALK therapy is 
one step removed, as trials testing its value as first-line therapy 
in advanced disease are ongoing.
2.3:  Recommendation.—Tissue should be prioritized for 
EGFR and ALK testing.
Evidence Grade: EGFR: A; ALK: B.—EGFR and 
ALK testing are the most important uses of the diagnostic 
sample after a diagnosis of adenocarcinoma is established. 
If specimens are insufficient for molecular testing, patients 
may need to undergo another invasive diagnostic procedure 
before they can be treated. Therefore, it is critical to retain 
sufficient material for molecular analysis and to be judi-
cious in the use of sections for IHC studies, histochemical 
stains, or deeper levels that may not be essential to establish 
a histopathologic diagnosis. This is particularly critical for 
specimens that have a limited amount of cancer cells. This 
concept has also now been incorporated into the new IASLC 
classification.63 In instances where there is not enough tis-
sue for EGFR and ALK testing, pathologists should alert 
the oncologist and include a note in the surgical pathology 
report to this effect. Because substantial tissue can be lost 
when blocks are refaced in histology laboratories while cut-
ting unstained slides after initial sectioning, consideration 
should be given to cutting multiple additional unstained sec-
tions “up front” when the sample is first processed in histol-
ogy. These unstained sections could then be used for deeper 
levels or additional histochemical/immunohistochemical 
stains as needed to establish the diagnosis, and for ensuing 
molecular testing, without having to reface and recut the 
blocks. The benefit of such a sample-sparing protocol must 
be balanced against the cost of cutting additional sections, 
some of which might not be used.
Question 3: How Rapidly Should 
Test Results Be Available?
3.1:  Expert Consensus Opinion.—EGFR and ALK 
results should be available within 2 weeks (10 work-
ing days) of receiving the specimen in the testing 
laboratory.
Clinical response to EGFR TKI in EGFR-mutated 
tumors is typically seen rapidly, and the drugs themselves have 
relatively modest side effects when compared to platinum-
based chemotherapy.89 For these reasons, some oncologists are 
willing to initiate EGFR TKI therapy before the EGFR test 
result is available. However, randomized controlled trials have 
demonstrated that EGFR wild-type tumors respond better to 
conventional chemotherapy than to EGFR TKIs.7,26,90,91 Thus, 
in most clinical circumstances, EGFR TKI therapy should 
not be administered as first-line therapy without evidence of 
a sensitizing EGFR mutation. Therefore, the turnaround time 
(TAT) for EGFR testing has become increasingly important, 
especially for patients with advanced-stage disease.
To that end, and in the absence of published data estab-
lishing an evidence-based recommendation, it is our expert 
consensus opinion that a TAT goal of 1 week (5 working 
days) should be established for EGFR and ALK testing, up 
to a maximum TAT of 2 weeks (10 working days). This TAT 
refers to the period from the receipt of suitable material by 
the molecular pathology laboratory where the testing is per-
formed to the reporting of the final results to the clinical care 
team, and is not related to the period of time between when a 
patient undergoes a diagnostic procedure and when a speci-
men is submitted to the laboratory for testing. We consider 
achieving this TAT goal to be most critical for patients with 
advanced-stage disease, although we believe it is a reasonable 
goal for all testing.
3.2:  Expert Consensus Opinion.—Laboratories with 
average TATs beyond 2 weeks need to make available 
a more rapid test—either in-house or through a refer-
ence laboratory—in instances of clinical urgency.
Patients with stage IV lung cancer have median 
untreated life expectancy of approximately 16 weeks; 20% of 
this time should not be spent waiting for test results. If labora-
tories cannot provide results for the sickest of patients within 
2 weeks, then they need to make available a method or another 
laboratory that can. This is particularly germane for large-
scale multiplexed assays that afford the capability of testing 
many genes at once, but may take several weeks to complete 
and analyze. While this technology has great scientific prom-
ise and platform consolidation is logistically appealing, the 
ability to generate large amounts of data of unproven signifi-
cance should not take precedence over the timely generation 
of clinically useful data. This recommendation is based upon 
expert consensus, given the lack of published experimental 
data addressing this topic.
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3.3: Expert Consensus Opinion.—Laboratory depart-
ments should establish processes to ensure that specimens 
that have a final histopathologic diagnosis are sent to 
outside molecular pathology laboratories within 3 work-
ing days of receiving requests and to intramural molecular 
pathology laboratories within 24 hours.
Another critical component of the overall testing time 
is the delivery of tissues necessary to perform these tests, 
both between institutions and within pathology departments. 
It is our expert consensus opinion that pathology depart-
ments should have established processes in place to retrieve 
and send out materials (blocks or unstained sections) within 
3 working days of receiving such requests, once a final his-
topathologic diagnosis has been established. In local cases, 
where tumor material must be transferred from surgical 
pathology or cytology to the molecular diagnostic labora-
tory, intradepartmental delivery of materials should occur 
within 1 working day for finalized current or recent (eg, not 
in long-term storage) cases. As stated above, reflex testing 
and/or preparation of unstained recut sections at the time the 
sample is first processed in the histology laboratory may help 
to ensure expedited and consistent intradepartmental routing 
of specimens for molecular testing.
Molecular pathology laboratories with high demand 
for these tests in otherwise busy pathology departments may 
benefit from having a specialized histologic service dedi-
cated to expeditious processing of samples for molecular 
testing within the pathology department or having a dedi-
cated histology technician and equipment within the molec-
ular pathology laboratory.
SeCTION II: HOW SHOUlD EGFR TeSTING 
Be PeRFORMeD?
Question 4: How Should Specimens Be 
Processed for EGFR Mutation Testing?
4.1:  Expert Consensus Opinion.—Pathologists should 
use formalin-fixed, paraffin-embedded (FFPE) speci-
mens or fresh, frozen, or alcohol-fixed specimens for 
polymerase chain reaction (PCR)–based EGFR muta-
tion tests. Other tissue treatments (eg, acidic or heavy 
metal fixatives, or decalcifying solutions) should be 
avoided in specimens destined for EGFR testing.
The effects of fixation and preanalytic specimen pro-
cessing are no different for EGFR mutation analysis than 
for other molecular diagnostics applications that rely upon 
PCR amplification, and EGFR testing can be performed on 
fresh, frozen, FFPE, or alcohol-fixed specimens. Accordingly, 
molecular tests should be validated for each of the specimen 
types likely to be encountered (ie, FFPE, fresh, frozen, alco-
hol fixed), and testing should be performed and reported only 
on validated specimen types. Other specimen types should be 
rejected as inadequate or tested at the discretion of the labora-
tory director, with clear communication that the test was per-
formed on a nonvalidated specimen type.
Fresh or frozen specimens are optimal for analysis of 
long (ie, >1000 bp) DNA segments.92–94 However, this is not 
typically necessary for EGFR testing. One drawback to test-
ing fresh or frozen tissues is the need for correlative histologic 
examination, which may require cutting and staining frozen 
sections flanking the portion of the specimen submitted for 
testing. In contrast, the use of FFPE material for DNA extrac-
tion allows a more convenient and accurate assessment of 
tumor content.
Different tissue fixatives, processing protocols, and 
storage conditions, with associated variations in chemical and 
physical conditions, including time to fixation, mechanism of 
fixation, processing temperature, pressure, and pH, storage 
time and conditions, all can affect the quality and quantity of 
DNA, RNA, and proteins in the specimens, and their analyses. 
Selection of a proper section for analysis, and correct interpre-
tation of negative results, requires that the molecular pathol-
ogy laboratory have access to this information.
Ten percent neutral-buffered formalin is the fixative 
that is most widely used, and most molecular assays have 
been optimized and validated on such tissues. Formalin fixa-
tion leads to chemical cross-links to proteins, RNA, and other 
DNA molecules, with concomitant fragmentation of DNA, 
which inhibits molecular analysis in a length-dependent fash-
ion. In general, molecular analyses of formalin-fixed DNA 
that require DNA segments shorter than 300 bp are usually 
successful, while those requiring a length between 300 and 
1000 bp succeed inconsistently, and those requiring a length of 
greater than 1000 bp are often unsuccessful.92 Formalin fixa-
tion also causes random nucleotide base changes, which can 
lead to false-positive results, typically in samples with low 
DNA concentration or with ultrasensitive assays.95–97
Alcohol (70% ethanol) has been shown to be compa-
rable to, if not better than, 10% neutral-buffered formalin for 
molecular assays requiring nucleic acid extraction, but alco-
hol is not a favored fixative in routine histology laboratories 
for a variety of reasons, including tradition, safety, cost, and 
compatibility with some other FDA-approved procedures (eg, 
ERBB2 [HER2/neu] FISH, estrogen receptor IHC).93,98 Most 
cytology fixatives are alcohol based and, therefore, cytology 
specimens are typically suitable for DNA-based molecular 
assays.99–101
Most molecular analyses are inhibited by heavy metal 
fixatives (eg, Zenker, B5, B plus, acid zinc formalin) owing 
to competition between the metals in the fixative and the 
magnesium needed as a cofactor for most DNA polymerases 
and other enzymes involved in molecular methods.93,102,103 
Specimens processed with heavy metal fixatives should not be 
used for EGFR testing.
Acidic solutions (eg, Bouin solution, bone-decalci-
fying solutions) fragment DNA extensively.104,105 Tissues 
treated with acidic solutions should not be used for EGFR 
testing. This is particularly problematic for analysis of bone 
metastases, which are usually decalcified in acidic solutions. 
The use of nonacidic chelating decalcifying solutions may 
better preserve DNA for molecular testing.105 Moreover, 
unbuffered formalin spontaneously oxidizes to formic acid 
over time.106
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The relatively broad time range of specimen fixation 
found in pathology practice usually has no effect on morpho-
logic details, but longer durations of fixation adversely affect 
the quality of nucleic acid.92 Fixation times of 6 to 12 hours 
for small biopsy samples and 8 to 18 hours for larger surgi-
cal specimens generally give best results, although our expert 
consensus opinion is that fixation times of 6 to 48 hours should 
give acceptable results, in accordance with CAP Laboratory 
Accreditation Program Checklist MOL.39358 for HER2/neu 
in situ hybridization.98,107 This is a generalization, however, 
and the effect of extreme fixation times should be assessed by 
each laboratory during validation. This knowledge should be 
incorporated into the interpretation and reporting of molecu-
lar pathology results when fixation times are extreme.
4.2:  Expert Consensus Opinion.—Cytologic samples 
are also suitable for EGFR and ALK testing, with cell 
blocks being preferred over smear preparations.
Although it has been shown that smears can be used 
effectively for DNA extraction for EGFR mutation assays, it 
is our expert consensus opinion that, for cytology specimens 
such as malignant pleural effusions, use of a cell block is rec-
ommended over smear preparations because of the ability 
to correlate with malignant cell content, the preservation of 
the original diagnostic specimen, and the possible retention 
of more material for additional diagnostic studies.62,101,108,109 
In addition, analysis of FISH requires nonoverlapping tumor 
cells, which can be a challenge to identify on 4′,6-diamidino-
2-phenyl-indole (DAPI)–stained smears. As with surgical 
pathology specimens, the cell pellet should be fixed in 10% 
neutral-buffered formalin for 6 to 48 hours before process-
ing. Fixation in 70% ethanol is also acceptable; in which case 
validation of the molecular assays on DNA extracted from 
alcohol-fixed tissues should be done.
Question 5: What Are the Specimen 
Requirements for EGFR Testing?
5.1:  Expert Consensus Opinion.—Pathologists should 
determine the adequacy of specimens for EGFR 
testing by assessing cancer cell content and DNA 
quantity and quality.
EGFR mutation testing can be performed on specimens 
procured by almost any procedure: surgical resection, open 
biopsy, endoscopy, transthoracic needle biopsy, fine-needle 
aspiration, or thoracentesis. In general, larger tumor specimens 
(eg, resections) are generally preferred for mutation assays 
because of greater amount of material and greater capacity 
to enrich the malignant content by dissection. However, most 
advanced-stage lung tumor specimens are small biopsy or 
cytology specimens such as pleural fluids or fine-needle aspi-
rates. EGFR mutation assays have been shown to be able to 
detect mutations from cytologic specimens, particularly if cell 
blocks are available.109–114 Ultimately, any specimen that meets 
the laboratory’s requirements for tumor content, fixation, and 
quality, as established during validation, may be chosen for 
analysis. Specimens that fail to meet these requirements may 
be analyzed at the laboratory director’s discretion, but these 
specimens present some additional challenges that might 
necessitate additional testing procedures or communication in 
the report.
One of the issues with small specimens is the possibil-
ity of false-negative results.45,115–117 The number of tumor cells 
in comparison with normal tissue, such as inflammatory and 
stromal cells, is an important factor that influences the reli-
ability of mutational analysis.115 This is particularly important 
for less sensitive methods, such as unmodified direct DNA 
sequencing. In such cases, it may be appropriate to add to the 
report of a negative result a recommendation for repeated test-
ing on additional material if it becomes available.
Although PCR-based methods can in principle detect 
mutations from a single cell, a low copy number DNA tem-
plate can generate sequence artifacts, mainly guanine to ade-
nine transitions, due to stochastic occurrence of polymerase 
errors early in the PCR in the setting of low template.96 In 
addition, the DNA damage caused by formalin fixation can 
also lead to sequence artifacts.95 As much as 1 artificial muta-
tion per 500 bases may be observed in the analysis of for-
malin-fixed tissue with low DNA content.97 The frequency 
of errors reflects both Taq DNA polymerase’s normal error 
frequency and the degree of damage and cross-linking of 
DNA by formalin. For this reason, some laboratories perform 
duplicate amplifications of FFPE samples to ensure accu-
rate results. For direct DNA sequencing, mutational artifacts 
should be distinguished from true mutations by bidirectional 
sequencing and by confirmatory sequencing of independent 
PCR products.107 Whole genome amplification is a method 
to increase the amount of template DNA in insufficient 
specimens. It is prone to the same types of artifacts as PCR 
amplification of low templates and it is therefore prudent to 
analyze specimens in duplicate, beginning with a duplicate 
whole-genome-amplification step.118
Laboratories offering EGFR testing should determine 
the requirements for each type of specimen they may encoun-
ter (eg, fluids, fresh tissues, fixed tissues). All specimens from 
a patient should be considered for testing, and the choice of 
which specimen to test should be made by a pathologist famil-
iar with the molecular testing to be performed, based primarily 
upon tumor content and likely DNA quality as influenced by 
fixatives and other solutions used in histology.
If no adequate specimen is available and a new specimen 
needs to be procured, then the decision regarding which speci-
men to obtain is a complex one. Factors in this decision include 
the patient’s overall health, accessibility of lesions, radiographic 
appearance of lesions, and ability to schedule procedures 
promptly. The pathology factors that contribute to this decision 
include the minimum specimen requirements for each sample 
type, as well as the relative likelihood of each sample type meet-
ing these requirements. As such, it is important for the molecu-
lar pathologist to monitor the percentage of specimens that are 
being rejected as inadequate for each specimen type and to pro-
vide consultation to the oncology care team to assist in obtain-
ing the specimen type that is most likely to yield a diagnostic 
result. Although not a guideline recommendation, some pathol-
ogy departments may send a cytopathologist or cytotechnologist 
to provide immediate consultation in the clinic or interventional 
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radiology suite regarding adequacy of specimens obtained by 
needle biopsy procedures.
5.2:  Expert Consensus Opinion.—Each laboratory 
should establish the minimum proportion and number 
of cancer cells needed for mutation detection during 
validation.
The minimum percentage tumor cellularity require-
ments will depend on the methodology being used for analysis. 
In general, a minimum mutated allele frequency of 25% (50% 
cancer cell frequency, assuming heterozygosity and disomy) 
is required for unmodified Sanger sequencing, although this is 
a generalization and each laboratory must determine its sensi-
tivity cutoff for each assay.119 Several more sensitive mutation 
detection techniques have sensitivities in the range of 10% 
down to 1% or even lower.119–122 These are general approxi-
mations, however, and each laboratory must determine the 
minimum amount of tumor cells needed for analysis (analytic 
sensitivity) during validation, for each specimen type that will 
be accepted by the laboratory (fixed tissue, fresh/frozen tissue, 
fluid) and for each analyte measured. Ideally, these studies are 
performed with patient specimens, although cell lines may 
be necessary if appropriate patient specimens are not avail-
able. The use of plasmids is not recommended owing to an 
increased risk for intralaboratory contamination similar to that 
of PCR products.
Importantly, the association between mutated allele 
content and cancer cell content is significantly affected by 
genomic copy number changes. EGFR-mutated alleles are 
often amplified.123,124 While it might be ideal to determine 
the EGFR copy numbers for the validation specimens (ie, 
by FISH) and use disomic tumors for sensitivity assessment, 
this may not be practical for most laboratories, in which case 
the sensitivity studies should be performed with more than 1 
specimen, to control for the variation in EGFR copies between 
tumors or cell lines.
In addition to establishing the analytic sensitivity of the 
EGFR testing method during validation, the performance of 
the assay also needs to be monitored in an ongoing fashion 
once clinical testing is initiated. Accordingly, a low-positive 
control specimen (near the lower limit of tumor content of 
specimens accepted by the laboratory) should be tested in 
each clinical assay run.
5.3:  Expert Consensus Opinion.—A pathologist should 
assess the tumor content of each specimen and either 
perform, or guide a trained technologist to perform, 
microdissection for tumor cell enrichment as needed.
Appropriate assessment of the specimen is critical for 
accurate results and preventing false-negative results and 
assay failures. A representative stained slide must be reviewed 
by a pathologist to determine and document the cellular con-
tent and tumor purity in the focus of tissue to be tested. An 
ideal specimen would have not only a very high proportion 
of malignant cells relative to the admixed nonneoplastic cells, 
but also a minimal amount of substances that may inhibit 
amplification, such as mucin and necrotic tissue. In general, 
assessment of tumor content and purity is more accurate in 
fixed sections than in frozen sections, and this has prompted 
some laboratories to designate FFPE tumor material as the 
preferred specimen type.
Estimates of tumor content from hematoxylin-eosin–
stained sections vary considerably between pathologists.125 
Establishing gold standard calibration specimens through 
formal cell counting of selected areas can be used to train 
pathologists and assess their accuracy and precision. In the 
absence of a true standard, consensus opinion can be used 
to assess tumor content in a specimen near the threshold for 
acceptability.
Often, the entire tissue section may have a suboptimal 
proportion of tumor for analysis, but a subregion within the 
section may be more suitable, and an enrichment strategy 
must be used to isolate cells from the more concentrated area 
only. In this event, the tumor enrichment can be performed 
directly by the pathologist or by a trained technologist under 
guidance by the pathologist, in which case, the ideal region 
should be demarcated on the slide by a pathologist during 
their hematoxylin-eosin review of the case, with documenta-
tion of tumor content, and used as a reference for the tumor 
enrichment procedure. Tumor enrichment procedures should 
also be assessed during test validation.
Dissection of areas rich in tumor cells from surround-
ing normal tissue is the typical method for enriching a 
specimen for malignant DNA content. The main benefit of 
dissection is the production of relatively pure specimens of a 
morphologically confirmed cell population. Dissection meth-
ods include gross macrodissection or coring of an area out of 
tissue or a paraffin block, microdissection from glass slides, 
with or without visualization under a microscope, and flow 
cytometric sorting or laser capture microdissection (LCM) 
techniques to enrich the specimen cell by cell. Manual dis-
section is quick, relatively simple and requires inexpensive 
equipment such as a standard or inverted microscope. As dif-
ferent laboratories will have different resources available for 
this step, any method can be adopted for tumor enrichment, 
as long as the cellularity requirements for the assay are estab-
lished accordingly.
Laser capture microdissection is a time-consuming and 
labor-intensive method that requires expensive equipment. 
Although the actual microdissection is relatively simple, 
personnel must be specially trained to use the equipment. 
Another disadvantage of LCM is that DNA yield is often 
low. The main advantage of this technique is that a pure cell 
population with minimal normal tissue contaminants can be 
acquired. Small specimens, such as endobronchial or needle 
biopsies requiring LCM to isolate tumor cells, showed a high 
failure rate (53%–66%) by DNA direct sequencing in contrast 
to larger resection or excisional biopsy specimens (24%).126 In 
addition, LCM specimens typically have low DNA content, 
which can lead to assay imprecision and PCR artifacts that 
can be misinterpreted as unusual or novel mutations96,127 (see 
“Question 6” discussion below).
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Question 6: How Should EGFR 
Testing Be Performed?
6.1:  Recommendation.—Laboratories may use any vali-
dated EGFR testing method with sufficient perfor-
mance characteristics.
Evidence Grade: B.—Multiple test platforms are accept-
able for EGFR mutation testing, and this guideline does not rec-
ommend any individual method(s) to the exclusion of others. 
Rather, we recommend that tests offered for clinical care meet 
specified minimal performance characteristics, and require that 
laboratories establish acceptable performance during validation 
and maintain acceptable quality during production. The perfor-
mance characteristics that are most relevant for this discussion 
are sensitivity and specificity. Other test characteristics of par-
ticular importance are TAT and spectrum of mutations detected.
A variety of methods are used to detect EGFR muta-
tions, including Sanger sequencing with and without mutated 
allele enrichment, the amplification refractory mutation sys-
tem, length analysis, restriction fragment length polymor-
phism, real-time PCR, high-resolution melting curve analysis, 
single-base extension genotyping (including mass spectrom-
etry–based genotyping), and denaturing high-performance 
liquid chromatography, each having different advantages and 
disadvantages27,36,57,115,120,121,128–156 (Table 11). At the time of 
writing, published data on the application of massively paral-
lel sequencing to the detection of EGFR mutations were still 
quite limited but this technology is expected to soon become 
more widespread.157–159
6.2:  Expert Consensus Opinion.—Laboratories should 
use EGFR test methods that are able to detect muta-
tions in specimens with at least 50% cancer cell 
content, although laboratories are strongly encour-
aged to use (or have available at an external refer-
ence laboratory) more sensitive tests that are able to 
detect mutations in specimens with as little as 10% 
cancer cells.
The historical reference method, bidirectional sequence 
determination by the Sanger method with fluorescence-tagged 
dideoxy terminators, is usually able to precisely detect mutated 
sequences when they constitute approximately 25% of the 
total DNA (potentially even lower for specific nucleotide 
changes), which corresponds to a minimum tumor content of 
approximately 50% for a heterozygous mutation with no poly-
somy or amplification.160 Although this method, with this level 
TABle 11.  Comparison of Sanger Sequencing to Other Methods for the Detection of EGFR Mutationsa
Sanger Sequencing Versus Other 
Methods
Concordance of 
Methods, % n (N)
Seq−/
Other+
Seq+/
Other−
Incidence of EGFR 
Mutations, %
RR (95% CI) P Value
Sanger 
Sequencing
Other 
Method
PCR-based mutation detection
 Allele-specific PCR/ARMS130 73 1 (83) 18 4 16 33 0.48 (0.27–0.87) .01
 Real-time PCR119,304 97 2 (102) 2 1 26 27 0.94 (0.60–1.46) .78
 Cycleave PCR131,b 95 1 (195) 1 8 40 36 1.10 (0.85–1.41) .47
Post-PCR mutation detection
 Capillary electrophoresis296,304 98 2 (61) 1 0 16 18 0.91 (0.42–2.01) .82
 Restriction fragment length 
polymorphism133
99 1 (109) 1 0 33 34 0.97 (0.67–1.41) .89
 INVADER305,c 86 1 (42) 5 1 43 52 0.82 (0.52–1.29) .39
 Pyrosequencing159,306 96 3 (140) 6 0 16 20 0.78 (0.49–1.25) .30
Mutation scanning
 Denaturing HPLC139,307 94 2 (196) 12 0 20 27 0.66 (0.27–1.63) .37
 Single-stranded conformational 
polymorphism45
98 1 (375) 8 0 8 10 0.79 (0.51–1.25) .32
 High-resolution melting analysis121,135,308 83 3 (321) 54 0 36 53 0.70 (0.46–1.06) .09
 Loop-hybrid mobility shift assay309 100 1 (43) 0 0 26 26 1.00 (0.49–2.06) >.99
Mutant enrichment
 Peptide nucleic acid/locked nucleic acid 
amplification301,310
96 2 (150) 4 2 11 12 0.91 (0.49–1.67) .75
 COLD PCR138 100 1 (126) 0 0 10 10 1.00 (0.48–2.07) >.99
 Smart Amplification Process120,132,301 86 4 (220) 30 0 20 34 0.58 (0.44–0.77) <.001
Abbreviations: ARMS, amplification refractory mutation system; CI, confidence interval; COLD, coamplification at low denaturation temperature; HPLC, high-performance liquid 
chromatography; n, number of studies; N, number of patients; PCR, polymerase chain reaction; RR, relative risk, Mantel-Haenszel random effects model, (95% CI); Seq−, negative by 
Sanger sequencing; Seq+, positive by Sanger sequencing.
aThe variation in EGFR mutation rate between rows may reflect studies performed in different patient populations (Asian versus non-Asian). No statistical comparisons were 
performed between rows.
bCycleave; Takura Bio, Otsu, Shiga, Japan.
cInvader; Hologic, Madison, WI.
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of performance, was the initial method used to establish the 
value of the test for predicting response of tumors to erlotinib 
and gefitinib, many specimens fall short of this tumor con-
tent.47,161,162 As a consequence, laboratories exclusively using 
this method would have to reject a significant proportion of 
specimens as inadequate for testing.
All laboratories must establish the lower sensitivity of 
their methodology during test validation. Any tumor enrich-
ment procedures, such as manual microdissection, must be 
included as part of the validation. The sensitivity limit (also 
called analytic sensitivity) should be defined as the lowest 
concentration of tumor cells in which a mutation is detected 
with 100% precision in replicates repeated both within run 
and between run.107 As stated earlier, because of possible vari-
ation in the genomic copy number of mutated EGFR alleles 
between tumors, this cutoff should be validated on more than 
1 tumor specimen. Wild-type results above this limit can be 
reported confidently as negative.
Although the published evidence supports a recom-
mendation that any method must be at least as sensitive as 
the Sanger sequencing technique that first established the 
clinical value of mutation detection, our expert consensus 
opinion is that more sensitive methods should be available, 
because of the many patients who only have had samples 
with low tumor content.115,163 In our opinion, an ideal test 
should be able to detect mutations in specimens with as lit-
tle as 10% cancer cells. In particular, laboratories that use 
Sanger sequencing are strongly encouraged to use a mutated 
allele–enriching strategy, such as locked nucleic acid or 
peptide nucleic acid clamps, coamplification at lower dena-
turation temperature PCR, or enzymatic digestion of wild-
type sequences, to enhance the sensitivity for the common 
critical mutations in exon 19 (747_750 LREA deletions), 
20 (T790M), and 21 (L858R).70,156,164 If a laboratory can-
not offer a more sensitive method than unmodified Sanger 
sequencing, then that laboratory must communicate its limi-
tation clearly to its clinicians and make available referral to 
another laboratory for more sensitive testing for specimens 
with lower tumor content.
Although analytic sensitivity is very important for 
expanding testing to patient specimens with low tumor con-
tent or purity, ultrasensitive molecular assays (defined here as 
an analytic sensitivity of below 1%) can be problematic. In 
specimens with high tumor content, if an ultrasensitive molec-
ular assay finding is positive while an assay finding of con-
ventional sensitivity is negative, the result is either interpreted 
as a possible false positive due to mispriming or low cross-
contamination, or as a true positive reflecting a very small 
mutated subclone. Thus, there is a risk of losing specificity 
with regard to predicting response to targeted therapy. Some 
studies using such methods have found novel, possibly artifac-
tual mutations, or failed to show a relationship between classic 
EGFR mutations and treatment response.165 Finally, technical 
artifacts may be seen with ultrasensitive methods that require 
experience and caution in interpretation.
Accordingly, specificity of ultrasensitive methods must 
receive additional attention during validation. Multiple nega-
tive lung cancer specimens should be tested, as should no-tem-
plate controls. Given the huge collective testing experience 
accumulated and reflected in online databases such as the 
Catalogue of Somatic Mutations in Cancer (COSMIC), novel 
EGFR mutations are rare today, and the discovery of novel 
mutations is cause for careful scrutiny and reevaluation of 
methodology. Artifacts should be presented in the laboratory’s 
standard test operating procedure manual to assist in inter-
pretation, and laboratories should clearly communicate with 
clinicians when results are unclear or uncertain.
Although not a guideline recommendation, a suggested 
approach is to offer a 2-tiered testing strategy, in which both 
standard-sensitivity and high-sensitivity testing is performed 
and reported. An example would be Sanger sequencing with, 
and without, mutated enrichment by locked nucleic acid/pep-
tide nucleic acid. The report would then indicate whether a 
mutation was detected only with the ultrasensitive method or 
also by the less sensitive method, which could then be corre-
lated with the morphologic estimate of tumor content.
Each laboratory should have a dialogue with its clini-
cians to understand the TAT needs within its health care set-
ting. If results are needed within a few days, then multistep 
testing such as Sanger sequencing may be less desirable than 
a 1-step procedure such as allele-specific PCR. Similarly, if a 
sample has borderline tumor content for the method in ques-
tion and TAT is critical, it may be better to go directly to a 
more sensitive method or have the patient undergo another 
sampling procedure, rather than attempt an analysis that may 
end up with an inconclusive interpretation.
6.3:  Expert Consensus Opinion.—Clinical EGFR muta-
tion testing should be able to detect all individual 
mutations that have been reported with a frequency of 
at least 1% of EGFR-mutated lung adenocarcinomas.
Another critical issue in method selection is the spec-
trum of mutations tested. This is not a concern for Sanger 
sequencing, which provides information on mutations 
throughout the exons sequenced (usually exons 18 to 21), 
but it is an important consideration in the selection or design 
of mutation-specific assays. The 2 most common mutations 
in EGFR, the short in-frame deletions in exon 19 and the 
L858R point mutation in exon 21, account for about 90% of 
all EGFR mutations, and these are the mutations with by far 
the most extensive data on EGFR TKI response rates (Table 
12). Nonetheless, response data are accumulating for other 
less common mutations and therefore, our consensus opinion 
is that limiting testing to the 2 major mutations is no longer 
considered acceptable.
Routine EGFR assays for EGFR exon 19 deletions 
should be designed to detect not just the common 15-bp and 
18-bp deletions, but also the less common 9-, 12-, 24-, and 
27-bp deletions, as well as the uncommon 15-bp and 18-bp 
insertions.166 EGFR exon 18 should be analyzed for E709 
and G719 mutations; exon 20 for S768, T790M, and inser-
tions; and exon 21 for L858R, T854, and L861Q mutations. 
Pretreatment T790M mutations and most exon 20 insertions 
are associated with lack of response to first-generation EGFR 
TKIs, and this should be communicated in the report.137,167–169
Given the accumulated experience with EGFR muta-
tions, the detection of “novel” mutations or mutations only 
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reported very rarely should be viewed with great caution and 
should prompt replicate assays on new DNA extracts to rule 
out artifactual mutations due to formalin fixation, PCR errors, 
or whole-genome-amplification errors (if used). Nevertheless, 
rare variants and rare mutations will occur, and such findings 
should not be automatically discarded as errors.
The recommendation for broad mutation detection may 
conflict with the recommendation for TAT. In these instances, 
laboratories may consider offering 2 assays: a rapid assay for 
the most common mutations, which can be reported within a 
few days in cases of clinical urgency, and a more comprehen-
sive follow-up assay to detect the remaining mutations, which 
may take longer to report.
6.4:  Recommendation.—Immunohistochemistry for total 
EGFR is not recommended for selection of EGFR 
TKI therapy.
Evidence Grade: A.—Interest in IHC-based testing is 
driven by the fact that it is a technology available to essentially 
all pathology departments, and it can be performed for speci-
mens where the number or proportion of tumor cells poses 
challenges for molecular tests based on bulk DNA extrac-
tion from tissue. There are 3 main types of EGFR IHC: IHC 
for total EGFR, IHC for phosphorylated EGFR, and IHC for 
mutated forms of EGFR.
Immunohistochemistry for total EGFR is not an accept-
able test for EGFR TKI treatment selection because it has 
been shown to correlate poorly or not at all with the pres-
ence of EGFR mutations.123,170,171 However, in other settings, 
the role of IHC for total EGFR may need to be reassessed in 
the future if the anti-EGFR monoclonal antibody cetuximab 
becomes a therapeutic option in mutation-negative, EGFR-
overexpressing patients.172
Experience with IHC for phosphorylated EGFR is still 
limited and concerns remain regarding the stability of phos-
phorylation status in routinely handled pathology material. 
Use of such IHC assays for EGFR TKI treatment selection 
would be premature at this point.
The third type of IHC assay that has been evaluated uses 
commercially available mutation-specific rabbit monoclonal 
antibodies directed against the most common mutated forms 
of EGFR: the 15-bp/5-amino-acid deletion (E746_A750del) in 
exon 19 and the L858R point mutation in exon 21.173 In several 
independent studies,173–175 IHC with the EGFR L858R mutated 
antibody has confirmed excellent sensitivity and specificity 
relative to mutation testing. The EGFR exon 19 mutated–spe-
cific antibody showed excellent sensitivity and specificity for 
cases with the 15-bp deletion in exon 19 but reduced sensi-
tivity for exon 19 deletions of other sizes.174,176–178 If scoring 
cutoffs are set stringently to ensure a high positive predictive 
value, IHC with EGFR mutation–specific antibodies could be 
used as an initial screen to identify most patients who are can-
didates for EGFR inhibitors; however, for all specimens nega-
tive with these 2 mutation-specific monoclonal antibodies, 
that is, most samples overall, molecular testing is still needed. 
In the absence of an algorithm that includes molecular test-
ing of negative cases, mutated EGFR allele-specific IHC is 
currently too insensitive to be used as a stand-alone assay for 
TABle 12. EGFR Mutations Accounting Individually for at 
Least 1% of All EGFR Mutations
EGFR 
Exon EGFR Codon
Mutationsa 
(Amino Acid)
Nucleotide 
Substitutions
Approximate 
% of All 
EGFR 
Mutations
18 E709 E709K c.2125G>A 1
E709A c.2126A>C
E709G c.2126A>G
E709V c.2126A>T
E709D c.2127A>C, 
c.2127A>T
E709Q c.2125G>C
G719 G719S c.2155G>A 2–5
G719A c.2156G>C
G719C c.2155G>T
G719D c.2156G>A
19 K739 Insertions 1
I740 18-bp ins
P741
V742
A743
I744
E746 Deletions 45
L747 15-bp del
R748 18-bp del
E749 9-bp del
A750 24-bp del
T751 12-bp del
S752
P753
20 S768 Insertions 4–10
V769
D770
N771
P772
H773
V774
S768 S768I c.2303G>T 1–2
T790 T790M c.2369C>T 2b
21 L858 L858R c.2573T>G 40
L858M c.2572C>A 
(rare)
L861 L861Q c.2582T>A 2–5
L861R c.2582T>G
Abbreviations: del, deletion; ins, insertion.
aExplanatory note.
bExplanatory note.
Notes and footnotes: All mutations listed are generally associated with sensitivity to 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) except T790M 
and exon 20 insertions. G719 and L861 mutations are considered sensitive but somewhat 
less so than the major exon 19 and 21 mutations. Because exon 20 insertions appear 
largely insensitive to erlotinib and gefitinib and do not coexist with other mutations, it 
may be acceptable to exclude them from a testing panel at this time. However, exon 20 
insertions are variable in exact position and structure, and response data remain very 
limited for some types of insertions; therefore, some oncologists may recommend a trial 
of a first- or second-generation EGFR TKI. Mutations at E709 and S768 usually occur in 
combination with another of the listed. Data derived from Chen et al110; He et al166; Oxnard 
et al210; Wu et al278; Bamford et al311; De Pas et al312; and Murray et al.313
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EGFR TKI treatment selection. However, for patients with 
only a low cellularity specimen deemed inadequate for DNA 
analysis, this IHC may be the best option available, but there 
is still no prospective clinical experience with this special situ-
ation.179 Overall, the body of published data is insufficient to 
make an evidence-based recommendation regarding the use of 
EGFR mutation–specific IHC at this time. Laboratories that 
plan to use these antibodies clinically should validate their 
use against a valid molecular assay, communicate their clini-
cal performance characteristics (eg, sensitivity, specificity) to 
their clinicians, and make available referral to another molec-
ular laboratory for molecular testing to exclude mutations in 
IHC-negative tumors (if not available in-house).
6.5:  Recommendation.—EGFR copy number analysis 
(ie, FISH or chromogenic in situ hybridization) is not 
recommended for selection of EGFR TKI therapy.
Evidence Grade: B.—Increased EGFR gene copy number 
(polysomy or amplification) is observed in about 40% of cases, 
with a range of 8% to 66%.54,129,180–182 Across multiple studies, 
the EGFR TKI response rates for patients with EGFR poly-
somy/amplification is 30% (Table 13), consistently well below 
the mean response rate seen for patients with EGFR mutations 
(68%) (Table 1). Amplification of the mutated EGFR allele is 
common and drives a strong statistical association of EGFR 
polysomy/amplification with EGFR mutation.170,171 The correla-
tion of EGFR polysomy/amplification with EGFR TKI response 
is secondary to this strong association with EGFR mutation, 
and in the cases where EGFR mutation and copy number are 
discrepant, the mutation status is better associated with EGFR 
TKI response.170,171 In studies with data on both, EGFR TKI 
response rates for cases with EGFR polysomy/amplification and 
wild-type EGFR sequence are very low, essentially in the range 
of EGFR-nonmutated cases without increased EGFR copy 
number.170,171 In contrast, EGFR-mutated cases lacking amplifi-
cation show response rates comparable to EGFR-mutated cases 
overall.170,171 Finally, comparisons of EGFR amplification and 
EGFR mutation as predictors of response and clinical outcome 
in earlier clinical trials of TKI versus placebo in the second-line 
(or greater) setting were hampered by the small size of the 
subsets of patients with available molecular data, in particular 
mutation data.4,6,163 The IPASS study, a large phase III random-
ized clinical trial with data on both EGFR mutation and ampli-
fication, showed that EGFR TKI treatment selection based on 
mutation status leads to better clinical outcomes in the first-line 
setting than selection based on EGFR gene copy number, and 
subsequently published large phase III randomized controlled 
trials of TKI treatment response in the first-line setting used 
mutation analysis.7,26,90,91,183–185 Thus, EGFR copy number test-
ing, whether by FISH or chromogenic in situ hybridization, is 
less predictive than mutation testing and should not be used as a 
method for EGFR TKI treatment selection.170,171 More study is 
needed to determine if mutated allele copy number is a modifier 
of benefit in the setting of EGFR mutation.
Question 7: What Is the Role of KRAS 
Analysis in Selecting Patients for 
Targeted Therapy With eGFR TKIs?
7.1:  Recommendation.—KRAS mutation testing is not 
recommended as a sole determinant of anti-EGFR 
TKI therapy.
Evidence Grade: B.—The most common (~30%) onco-
gene mutated in lung adenocarcinomas is KRAS. The fre-
quency of KRAS mutations varies between ethnic groups; 
they are less frequent in Asians (5%–10%) when compared 
with individuals of white European or white American ances-
try (25%–35%) and African ancestry (15%–25%).25,186–188 
Approximately 90% to 95% of patients with KRAS-mutated 
lung adenocarcinomas have a history of tobacco use and there-
fore, regional differences in the proportions of KRAS-mutated 
lung adenocarcinomas may also reflect variations in smok-
ing prevalence, but KRAS mutations can also be observed in 
approximately 5% of lung cancer patients who never smoked 
tobacco.189,190 The substantial cumulative clinical experience 
and published data have shown that EGFR and KRAS muta-
tions are mutually exclusive.
TABle 13.  Different Outcomes of Tyrosine Kinase Inhibitor Therapy for Patients Tested by EGFR Fluorescence In Situ 
Hybridization (FISH)a
Outcome
Mean ± SD Percentage
n (N)
Risk Ratio M-H,  
Random (95% CI)
P 
Value
EGFR FISH+  
(High Copy No.)
EGFR FISH–  
(Low Copy No.)
EGFR FISH+  
(High Copy No.)
EGFR FISH–  
(Low Copy No.)
Response rate, %b 30 9 11 (861) 2.69 (1.86–3.90) <.001
Disease control rate, %c 47 24 5 (438) 2.09 (1.63–2.69) <.001
Overall survival at 1 y, %d 68 37 1 (183) 1.83 (1.37–2.44) <.001
Time to progression/progression-free  
survival, moe
2.9 ± 0.7 7 (638) 4.06 (1.97–6.16) <.001
Median survival time, mof 10.3 ± 3.4 8.7 ± 2.4 8 (778) 1.54 (−1.83 to 4.91) .37
Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel; n, number of studies; N, number of patients; Random, random effects model; SD, standard deviation.
aFISH scored according to the criteria of Cappuzzo et al.251
bReferences 28, 180, 191, 193, 195, 197, 198, 251, 314–316.
cReferences 191, 193, 195, 279, 314.
dReference 193.
eReferences 28, 185, 191, 193, 251, 316, 317.
fReferences 28, 180, 185, 191, 193, 197, 316, 317.
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Several studies compared response rates, PFS, and over-
all survival in patients with KRAS-mutated lung cancer treated 
with EGFR TKI, and 2 meta-analyses addressing these ques-
tions have been reported.28,180,191–201 The association between 
KRAS mutations and a lack of response to EGFR TKI was 
based on retrospective reviews of EGFR TKI in the second- and 
third-line setting.28,180,191–193,195–202 Objective response to EGFR 
TKI can be seen in 0% to 3% of patients with KRAS mutations 
and 26% of patients with KRAS wild type.28,180,191–193,195–202
In part because of the ease of testing for KRAS codon 
12 and 13 mutations and its widespread availability owing to 
indications in metastatic colorectal cancer, testing for KRAS 
mutations as a negative predictor of response to EGFR TKI 
has become part of molecular diagnostic algorithms for lung 
adenocarcinoma in many centers. However, with more recent 
data showing that EGFR wild-type tumors have less favorable 
outcomes if they are treated with EGFR TKI than if they are 
treated with conventional platinum-based chemotherapy, the 
decision to treat with an EGFR TKI can no longer be made 
without an EGFR result, and the role of KRAS testing in this 
context has diminished.26,90,91 The significance of KRAS muta-
tional analysis may become increasingly important with the 
further development of new therapies targeting downstream 
RAS pathways such as PI3K/AKT/mTOR and RAS/RAF/
MEK, but at this time, the absence of a KRAS mutation does 
not add clinically useful information to the EGFR mutation 
result and should not be used as a determinant of EGFR TKI 
therapy. However, because KRAS and EGFR mutations are 
mutually exclusive, a rapid and inexpensive KRAS assay may 
be performed initially to exclude KRAS-mutated tumors from 
EGFR mutation testing as part of an algorithm designed to 
maximize testing efficiency, provided that the sample is suf-
ficient to perform the KRAS test without sacrificing EGFR 
and ALK testing, and that the totality of clinically relevant 
molecular results can be obtained within the target TAT.
There are other clinical settings in which KRAS mutation 
has been examined as a biomarker that are not directly related 
to the present guidelines. In patients without EGFR mutations 
for whom chemotherapy fails, erlotinib may be administered 
as a second-line agent. In these patients, KRAS mutation may 
presage a poorer outcome, although the evidence for this from 
the BR21 trial is limited by small sample size and lack of sta-
tistical significance.170 KRAS mutation is also not predictive 
of benefit (or lack of benefit) from cetuximab therapy in lung 
cancer patients.172,203
Question 8: What Additional Testing 
Considerations Are Important in the Setting of 
Secondary or Acquired eGFR TKI Resistance?
8.1: Recommendation.—If a laboratory performs testing 
on specimens from patients with acquired resistance (AR) 
to EGFR kinase inhibitors, such tests should be able to 
detect the secondary EGFR T790M mutation in as few as 
5% of cells.
Evidence Grade: B.—Although clinical and radiographic 
responses to EGFR TKIs in patients with “sensitizing” EGFR 
mutations are significant in approximately 70% of cases, these 
patients almost invariably experience recurrence or progres-
sion while on treatment after a median of 8 to 16 months, a 
clinical phenomenon termed acquired resistance.137,204–206 
Clinical management implications of AR mechanisms are still 
evolving without established treatment guidelines; additional 
tumor material may be procured in this clinical setting in the 
course of diagnostic or therapeutic procedures, such as biop-
sies, to confirm recurrence or metastasis, or management of 
malignant effusions. In the event that tumor specimens from 
AR patients are tested, the following suggestions are included 
in this guideline.
The most common mechanism of AR involves the emer-
gence of an additional EGFR tyrosine kinase domain muta-
tion, T790M, caused by a single base substitution, C to T, at 
nucleotide 2369; this mutation is found as a second mutation 
on the EGFR allele harboring the initial “sensitizing” EGFR 
mutation.137,168,207 Because AR is, within the tumor cell popu-
lation, a subclonal process, that is, it is driven by the selec-
tion and outgrowth of a subclone of tumor cells that harbor 
T790M that confers a survival advantage in the presence of 
EGFR TKI, the technical sensitivity of the detection method 
is even more critical than in the testing for baseline, sensi-
tizing EGFR mutations that are present in every tumor cell. 
Initial reports found this mutation in approximately 50% of 
tumors at the time of treatment failure.137,168 However, because 
T790M is often not present in every tumor cell, conventional 
Sanger sequencing, even with microdissection, is considered 
insufficient for this testing.207 More recent studies based on 
higher sensitivity approaches place the prevalence of T790M 
in AR samples in the 60% to 70% range.208 In vitro studies 
have shown that cell population–level EGFR TKI resistance 
becomes detectable in the presence of as little as 5% T790M-
bearing cells and, in the absence of further clinical data, our 
consensus opinion is that assays for T790M should have sen-
sitivity to detect mutations in 5% of cells.209 This means that 
unmodified Sanger sequencing alone is insufficient, and labo-
ratories using Sanger sequencing should consider a mutation-
enriching strategy such as peptide nucleic acid/locked nucleic 
acid clamps, or have a more sensitive assay (eg, allele-specific 
PCR) that targets the T790M mutation in the setting of AR.
Most studies have only rarely detected T790M in pre-
treatment samples.210 When it is detected in the pretreatment 
setting, it should be confirmed as either somatic or germline 
by testing of normal DNA from the patient. Germline T790M 
mutation has been associated with familial lung cancer, and 
therefore its detection should trigger evaluation of the family 
history and genetic counseling, keeping in mind that risk esti-
mates and screening recommendations for unaffected T790M 
carriers remain to be determined.210,211
Other rare second-site mutations in the EGFR tyrosine 
kinase domain have been described in AR specimens, includ-
ing L747S, D761Y, and T854A, but owing to their relatively 
low prevalence, there is not much clinical experience with 
these and insufficient data have been published to formulate 
an evidence-based recommendation.212
A less common mechanism of EGFR TKI resistance is 
amplification of another receptor tyrosine kinase, most often 
MET or ERBB2. In initial reports, MET amplification was 
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reported in up to 20% of AR cases, with a portion of these also 
harboring the EGFR T790M mutation, but more recent studies 
suggest this number is closer to 10%.71,204,213,214 However, there 
is currently a lack of a precise definition of clinically signifi-
cant MET amplification in this setting and more research is 
needed before guidelines can be formulated. More recently, 
ERBB2 amplification has been reported in another subset of 
AR cases.318
Several clinical trials aimed at overcoming these distinct 
mechanisms of AR are underway and it is therefore likely that 
the further management of these patients will soon require 
determining T790M status and amplification of other receptor 
tyrosine kinases. T790M status may also become important in 
determining whether first-line EGFR TKIs should be contin-
ued in patients with AR. Recent data suggest that AR patients 
with the T790M mutation can derive continued clinical benefit 
from the first-line EGFR TKI.209,213
Interestingly, SCLC histology and associated “SCLC-
type” radiosensitivity and chemosensitivity have been 
observed in some AR cases, further supporting the notion that 
biopsy of recurrent tumor can be clinically valuable in AR.213
SeCTION III: HOW SHOUlD AlK TeSTING 
Be PeRFORMeD?
Question 9: What Methods Should 
be Used for ALK Testing?
9.1:  Recommendation.—Laboratories should use an ALK 
FISH assay using dual-labeled break-apart probes 
for selecting patients for ALK TKI therapy; ALK 
immunohistochemistry, if carefully validated, may 
be considered as a screening methodology to select 
specimens for ALK FISH testing.
Evidence Grade: B.—The genetic alteration of ALK in 
lung adenocarcinoma is due to chromosomal rearrangement. 
The most common of these rearrangements involves a peri-
centric inversion on the short arm of chromosome 2, inv(2)
(p21p23), which creates a fusion gene encoding the amino-
terminal portion of EML4 (2p21) and the intracellular region 
of ALK (2p23), genes that are normally approximately 13 Mb 
apart.8,215 Although the EML4-ALK fusion is the most com-
mon, other less common variant fusions have been reported, 
including translocations with other chromosomes (KIF5B-
ALK, TFG-ALK).215,216 The NPM-ALK translocation that has 
been well characterized in anaplastic large cell lymphoma 
(for which the gene was named) has not been reported in lung 
cancer.
FISH was the methodology used in the initial studies 
that demonstrated improved clinical response of patients with 
ALK-rearranged tumors to treatment with crizotinib, a targeted 
ALK TKI.15,17,217 Although FISH assays have been developed 
by using both break-apart and fusion strategies, the break-
apart assay design has shown the best association with clinical 
outcome.12,218 A commercial assay (Abbott Molecular Probes, 
Abbott Park, IL) is available that contains a SpectrumOrange-
labeled 300-kb probe on the telomeric 3′ side of ALK and a 
SpectrumGreen-labeled 442-kb probe on the centromeric 5′ 
side. With this probe set, the wild-type configuration appears 
as a fused yellow signal, while ALK rearrangement is seen 
as distinct and separated orange and green signals (Figures 
1 through 4). In the USA, FDA has approved this commer-
cial assay as a “companion diagnostic” to select patients to 
receive an FDA-approved ALK TKI. The published evidence 
FIGURe 1. Negative for ALK rearrangement (original magnifi-
cation ×1000).
FIGURe 2. Positive for ALK rearrangement (split 3’ ALK-5’ ALK) 
(original magnification x1000).
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indicates that this FISH assay is an acceptable means of select-
ing patients for treatment with an ALK TKI.
Whether or not the FDA-approved commercial assay 
is used, for accurate and precise results, the probe set used 
for clinical testing should be characterized in detail and the 
signal configurations and cutoff values for detecting ALK 
rearrangement should show reproducible performance with 
normal controls and known abnormal patient specimens and 
cell lines. If another set of probes or assay design is used, 
validation studies should demonstrate comparable or supe-
rior performance when compared to the commercial probes 
with regard to signal intensity, magnitude of signal split-
ting in positive cases, analytic precision, clinical sensitivity, 
and clinical specificity in accordance with published stan-
dards.219,220 For laboratories that elect to use laboratory-devel-
oped probes for ALK FISH testing, attention should also be 
given to batch variability of clones, DNA-labeling enzymes, 
and other reagents. Moreover, any laboratory-developed tests 
should retain the ability to detect variant fusions of ALK with 
partners other than EML4.
IHC-mediated identification of lung adenocarcinomas 
with overexpression of ALK has been investigated as a sim-
pler, quicker, and cheaper alternative to FISH-based identifi-
cation of ALK rearrangements. However, IHC studies using 
the anti-ALK1 antibody typically used for anaplastic large 
cell lymphoma (mouse monoclonal anti-human CD246, 
clone ALK1) have been disappointing, likely due to the low 
expression level of the fusion protein in ALK-rearranged 
lung adenocarcinomas in comparison to anaplastic large 
cell lymphoma.11,79,216,221–223 A substantial proportion of ALK-
rearranged lung adenocarcinomas are not identified by the 
ALK1 antibody, using standard techniques, and thus it is not 
reliable for ALK rearrangement screening in this setting.
To improve the sensitivity of detection of the ALK rear-
rangement by IHC with the commercially available ALK1 
antibody, some groups have developed alternative methods, 
including an intercalated antibody-enhanced polymer method, 
tyramide amplification, and an enhanced polymer-based 
detection system, with subsequent triaging of equivocal cases 
for ALK FISH.15,216 The current data are still limited and more 
studies need to be published to recommend this approach with 
this antibody.
A different antibody to ALK (mouse monoclonal, clone 
5A4) has been reported to have excellent sensitivity and 
specificity relative to ALK FISH results, at least for strong 
IHC staining and for negative or weak IHC staining, while 
intermediate IHC staining results were poorly predictive of 
ALK rearrangement status.221 High sensitivity, specificity, and 
reproducibility, as compared to FISH, have been shown with 2 
rabbit monoclonal anti-human ALK antibodies (clones D5F3 
and D9E4), and the former, ALK antibody D5F3, has just 
recently become commercially available.221
Based on promising recent results with these newer 
monoclonal antibodies, IHC assays hold the potential to 
facilitate the routine identification of ALK-rearranged lung 
adenocarcinoma. Where sensitive IHC assays are avail-
able, our consensus opinion is that a properly validated 
IHC method may be used as a screening modality, and that 
tumors that fail to demonstrate ALK immunoreactivity with 
a sensitive IHC method need not be tested for ALK rear-
rangement by FISH. The use of sensitive ALK IHC assays 
as screening tests has been adopted in some countries. Our 
opinion is that tumors that are positive for ALK IHC, either 
weakly or strongly, should still be referred to FISH for con-
firmation of a rearrangement. At this time, there are insuf-
ficient data available to develop a specific recommendation 
FIGURe 3. Positive for ALK rearrangement (single 3’ ALK) (origi-
nal magnification x1000).
FIGURe 4. Negative for ALK rearrangement with ALK high 
copy number (original magnification x1000).
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on the use of ALK IHC as a sole determinant of ALK TKI 
therapy.
9.2:  Recommendation.—RT-PCR is not recommended as 
an alternative to FISH for selecting patients for ALK 
inhibitor therapy.
Evidence Grade: B.—RT-PCR is not currently recom-
mended as a first-line diagnostic method for determining 
ALK fusion status because of concerns for a higher failure 
rate of an RNA-based assay in routine FFPE pathology mate-
rial, and the risk of false negatives, owing to variability in the 
EML4-ALK fusion structure and the existence of other ALK 
fusion partners. To date, there have been at least 13 molecular 
variants of EML4-ALK reported, representing chimeric tran-
scripts fusing EML4 exons 2, 6, 13, 14, 15, 17, 18, or 20 to 
ALK exon 20 or immediately upstream within intron 19 of 
ALK.222 Fusion of ALK to TFG and KIF5B has been reported 
in 1 case each, raising the likelihood that additional variant 
fusions may exist.215,216,224 It is possible to design multiplexed 
RT-PCR assays or to use multiple pairs of primers in separate 
or sequential reactions to detect the different EML4-ALK vari-
ants but multiplexed assays can be difficult to optimize and 
multiple separate assays may require more RNA than can be 
regularly extracted from small FFPE samples.
9.3:  Expert Consensus Opinion.—A pathologist should 
be involved in the selection of sections for ALK FISH 
testing, by assessing tumor architecture, cytology, and 
specimen quality.
Because cells are analyzed individually for evidence of 
ALK rearrangement using a fluorescent microscope, tumor 
percentage is not as critical for ALK FISH testing as it is for 
EGFR mutation testing. For ALK FISH, it is important to 
choose slides or regions of slides in which the tumor cells can 
be readily distinguished from admixed normal cells under flu-
orescence, typically through a combination of cytologic and 
architectural features that can be appreciated without stains or 
visualization of cytoplasm. In addition, areas should be cho-
sen in which tumor cells are not overlapping one another.
Specimen requirements for ALK FISH are generally 
similar to those for EGFR mutation testing: formalin fixation 
is acceptable, specimens should have enough cancer cells to 
analyze clearly, and DNA-damaging fixatives or acidic decal-
cifying agents should be avoided, as should specimens with 
abundant necrosis. Unlike EGFR mutation testing, however, 
FISH testing can be problematic when performed on alcohol-
fixed samples. Another important distinction between ALK 
FISH and EGFR mutation analysis is that FISH testing should 
ideally be performed on recently cut sections, although proto-
cols can be adapted to older slides.
Laboratories may follow the standard operating proce-
dures that have proven to be successful for FISH on forma-
lin-fixed, paraffin-embedded tissue sections in their setting. 
Attention must be paid to particular steps in the protocol that 
may affect probe penetration and hybridization to target DNA 
in order to optimize signal intensities.
Particular attention should be paid during validation to 
the choice of glass slides used for FISH. Several types of slides 
are manufactured for specialized applications at the expense 
of suitability for FISH. For example, some slides designed for 
tissue microarrays have a heavy coating that generates a fluo-
rescent matrix where tumor cells get embedded and cannot 
be properly treated for FISH-probe penetration. Other slides 
are designed for microdissection and do not hold the tissue 
adequately during pretreatment for FISH.
Modifications in the protease digestion protocol may be 
required, depending on the size of the tissue, duration and type 
of fixation, nuclear structure and tissue preservation, and time 
between sectioning and digestion. This may be particularly 
valuable with difficult sections, including cytology specimens 
and samples from bone biopsies. Tissue digestion should be 
standardized to maintain nuclear morphology. Overdigested 
chromatin may display artifactual “split signals” that may lead 
to false-positive findings.
Hybridization and washing steps should be standardized 
by using established protocols. Use of automated tissue pro-
cessors and standardized commercial tissue digestion kits can 
improve consistency and should be considered.
9.4: Expert Consensus Opinion.—A pathologist 
should participate in the interpretation of ALK FISH 
slides, either by performing the analysis directly or  
by reviewing the interpretations of cytogeneticists or 
technologists with specialized training in solid tumor 
FISH analysis.
The selection of nuclei to analyze is a step that is distinct 
from the scoring of probe signals. When evaluating the results of 
FISH, several factors should be kept in mind: the architecture of 
the tissue, including local variations in neoplastic cell content, 
fixation, and tumor cellularity within the section; the frequent 
presence of truncated nuclei; and the complex nature of cytoge-
netic arrangements such as heterogeneous increases in ploidy 
and aneusomy often seen in lung cancer. The FISH technologist 
should work closely with a pathologist who can identify tumor-
rich areas. Typically, areas selected for FISH evaluation will be 
marked on a hematoxylin-eosin–stained slide that is directly 
parallel to the section used for FISH. Areas of the FFPE section 
selected for signal scoring should pass rigorous quality criteria 
as being suitable for FISH analysis. Inclusion of macrophages 
or other nontumor cells in the analysis will dilute positive break-
apart scores and can lead to false-negative results. Experienced 
scorers who have undergone specific training in FISH in solid 
tumors should analyze the slides. The scorers should also have 
had training on the morphologic appearance of lung cancer, and 
should have easy access to assistance from a pathologist with 
training in FISH. Laboratories with experienced reviewers may 
use 1 scorer in cases with clearly negative or positive (>50% of 
cells) cases and a second scorer for less clear cases; otherwise 2 
independent reviewers are recommended.
Interpretation should be performed in areas of the 
slide with good signal, in which at least 50% of all nuclei 
are easily analyzable, with minimal background or nuclear 
fluorescent “noise.” The FISH signal intensity should be 
consistently greater than background intensity in the regions 
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of the slide chosen for analysis. Areas where the borders of 
individual nuclei are not clearly identifiable and/or high cell 
density causes excessive nuclear overlap are easy to misin-
terpret, and should be avoided. At the same time that the 
quality of the tissue section is reviewed, the FISH signals 
should be assessed, looking for areas with bright, distinct 
signals and low background in which individual nuclei are 
clearly distinguishable. Signals in a nucleus should in gen-
eral have the same intensity and the DAPI staining should 
be uniform.
Importantly, the interpretive criteria of FISH assays 
for ALK rearrangement in lung carcinoma are not necessar-
ily identical to those applied in other neoplastic diseases (eg, 
anaplastic large cell lymphoma, inflammatory myofibroblastic 
tumor), even if the identical FISH probe set is used. The most 
common positive result of a break-apart dual-labeled FISH 
assay in lung cancer will result in 1 separate orange/red and 
1 separate green signal (Figure 4). The native unaltered ALK 
region will remain as a yellow fusion signal but also com-
monly appears as 2 narrowly split orange/red and green sig-
nals. The second most common positive result in lung cancer 
is loss of the green 5′ probe with a remaining unpaired 3′ 
orange/red probe, indicating an unbalanced rearrangement. 
Importantly, proper interpretation of the FDA-approved com-
mercial break-apart assay considers only nuclei with loss of 
a green signal, or orange/red and green signals that are sepa-
rated by a gap larger than 2 signal diameters, to be indicative 
of an ALK gene rearrangement. Split signals of lesser magni-
tude separation are seen in the absence of ALK rearrangement 
and should not be interpreted as positive.15 The identification 
of a 2-diameter gap by readers requires experience, and inclu-
sion of well-characterized negative and positive control sec-
tions is an essential part of validating the assay.
Other observations likely to be encountered when scor-
ing signals include extra isolated 3′ ALK signals as well as extra 
signals (split and/or fusion) arising from polysomies, ploidy 
changes, and more complex ALK rearrangements.15 Currently, 
these findings are of uncertain significance. All results should 
be entered onto score sheets and should be coded.
In the trials demonstrating ability of ALK FISH to pre-
dict treatment response, a case was considered positive if 15% 
or more of 50 nuclei assessed in a tumor-rich portion of the 
section showed the classic split-signal pattern.15,217 Therefore, 
this cutoff is suggested and is part of the labeling of the FDA-
approved commercial assay. Laboratories should still validate 
clinically sensitive and specific cutoffs in their own hands and 
different cutoffs must be reconciled with those from the com-
mercial reference method. In certain situations with low tumor 
cell content, cutoffs as low as 5% may be considered, especially 
if IHC or RT-PCR results are available to support it, but this area 
requires more study. 
Limited data exist to recommend cutoff values for the 
other “nonclassic” patterns of ALK rearrangement, such as 
loss of 5′ signal, and all testing laboratories should establish 
their own cutoff values for these other patterns.
9.5:  Expert Consensus Opinion.—Testing for secondary 
mutations in ALK associated with acquired resistance 
to ALK inhibitors is not currently required for clinical 
management.
Several groups have reported a diverse set of second-
ary mutations in ALK that confer acquired resistance to crizo-
tinib, including L1152R, C1156Y, F1174L, L1196M, L1198P, 
D1203N, and G1269A.225–230 To date, however, the numbers of 
such cases are too small to recommend testing for these muta-
tions for routine clinical management, although we anticipate 
this indication to grow in the near future as effective second-
line therapies become available.
SeCTION IV: SHOUlD OTHeR GeNeS 
Be ROUTINelY TeSTeD IN lUNG 
ADeNOCARCINOMA?
Question 10: Are Other Molecular Markers 
Suitable for Testing in lung Cancer?
10.1a:  Recommendation.—Testing for EGFR should be 
prioritized over other molecular markers in lung 
adenocarcinoma.
10.1b:  Suggestion.—After EGFR testing, testing for ALK 
should be prioritized over other proposed molecu-
lar markers in lung adenocarcinoma, for which 
published evidence is insufficient to support testing 
guideline development at the present time.
Evidence Grade: EGFR: A; ALK: C.—Many additional 
molecular markers have been proposed as having value in 
management of lung cancer, in a variety of settings, including 
exposure to other molecularly targeted therapies, traditional 
chemotherapy, radiation, or surgery, as well as in other stages 
of disease and other histologic types of lung cancer. For each 
of these molecular markers, insufficient data have been pub-
lished to establish definitive recommendations as to where, 
when, and how they should be used. However, as discussed in 
the sections above, clear and compelling published evidence 
supports the need for EGFR and ALK testing of advanced-
stage lung adenocarcinomas as prerequisites to treatment 
with targeted TKIs. Precious tumor tissue must be reserved 
for these analyses, before any other molecular analysis is 
considered. Other tests may be performed in clinical trials or 
in clinical-pathologic contexts deemed appropriate by agree-
ment between pathologists and clinicians at each individual 
treatment center, provided sufficient material remains after 
the essential EGFR and ALK tests are completed.
SeCTION V: HOW SHOUlD MOleCUlAR 
TeSTING OF lUNG ADeNOCARCINOMAS Be 
IMPleMeNTeD AND OPeRATIONAlIZeD?
Question 11: Must All Adenocarcinomas 
Be Tested for Both EGFR and ALK?
11.1:  Expert Consensus Opinion.—Laboratories 
may implement testing algorithms to enhance 
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the efficiency of molecular testing of lung 
adenocarcinomas, provided the overall TAT 
requirements are met.
Currently, the higher costs and labor of simultaneous 
testing make it difficult to implement, in spite of its obvious 
advantage in TAT. Stepwise-testing algorithms make more 
efficient use of resources, but pose a challenge for timely 
delivery of final results. Given this time constraint, we rec-
ommend that stepwise-testing algorithms, if used, should 
nonetheless be completed within 10 working days. These 
algorithms are based on the observation that EGFR, ALK, 
and KRAS alterations are mutually exclusive, with very rare 
reported exceptions.217,231,232
The simplest algorithm would be to test for EGFR 
mutations first and proceed to ALK FISH if the EGFR results 
are wild type.
An alternative algorithm would involve an initial sen-
sitive and rapid EGFR mutation screening test by a method 
such as denaturing high-performance liquid chromatography, 
high-resolution melting analysis, or single-stranded confor-
mational polymorphism. Depending on assay design, these 
rapid screening methods could detect a mutation but fail to 
characterize it completely (ie, fail to define the size of an 
exon 19 deletion or distinguish between L858R and L861Q 
point mutations) or may be affected by single nucleotide 
polymorphisms (SNPs). For samples in which a mutation 
is detected but not adequately characterized, by a screening 
method, a more specific method, such as sequencing, would 
be performed to establish a definitive diagnosis. If the EGFR 
mutation screening test result is negative, then testing for ALK 
FISH should be performed. This involves an additional step, 
but would reduce the amount of definitive EGFR and ALK 
FISH testing considerably.
A third algorithm, slower still but potentially more 
cost-effective, would begin with a simple KRAS analysis. 
KRAS-mutated tumors, which represent 25% to 30% of lung 
adenocarcinomas and which do not have either EGFR muta-
tions or ALK rearrangements, would not proceed to either 
EGFR or ALK testing. The tumors without KRAS mutations 
would then enter into one of the algorithms above. If used, 
such an approach should still meet the above TAT recom-
mendations and should not be undertaken if the KRAS testing 
will exhaust the sample and thereby preclude EGFR and ALK 
testing.
Whether or not to use any of these, or other testing algo-
rithms, is a decision that each testing laboratory must make, in 
conjunction with its clinical care team, to balance its available 
resources and clinical needs within its individual health care 
setting.
Question 12: How Should EGFR 
and ALK Results Be Reported?
12.1:  Expert Consensus Opinion.—EGFR mutation test-
ing reports and ALK FISH reports should include a 
results and interpretation section readily understand-
able by oncologists and by nonspecialist pathologists.
Oncologists should be able to readily glean the informa-
tion needed to select appropriate therapy, and to explain the 
result to their patients. Pathologists should be able to learn 
sufficient details from the reports to help determine whether 
repeated testing is appropriate, or to help resolve discrepan-
cies between clinical and laboratory results or between tests 
performed at different laboratories.
The preclinical section of reports should include the 
standard identifiers of the patient and specimen, as well as 
an assessment of the specimen’s morphologic characteristics: 
diagnosis and tumor content (percentage of total nuclei that 
are malignant). In addition, histopathologic characteristics 
that may affect the interpretation should be mentioned, such 
as extensive necrosis, atypical specimen processing or fixa-
tion, or low total number of tumor cells.
The results section of reports should include, promi-
nently, the names of any clinically significant mutations 
identified, in formal Human Genome Variation Society 
(HGVS) nomenclature. Additional, more commonly used 
terminology may be included, as requested by each insti-
tution’s clinical care teams. Incidental findings, variants of 
uncertain significance, and benign polymorphic variants 
should be clearly presented as such, to leave the reader 
no doubt as to the lack of evidence supporting their role 
in clinical management. For multiplexed assays, ideally, 
results could be presented in a table listing each clinically 
significant variant that is assessed by the test, with an adja-
cent result for each. Inconclusive results should be clearly 
reported as such.
Reports should include a histopathologic assessment of 
tumor content for the tumor section tested and the reported 
result should include an overall statement of the cancer’s like-
lihood to respond or resist EGFR TKI therapy. If the result is 
inconclusive, whether due to assay failure or an insufficient 
specimen, or another reason, the interpretation should state 
why (as best as is known) and suggest requirements for test-
ing a different specimen that would be more likely to yield a 
successful result.
The technical section of the report should include 
enough information for another laboratorian to understand 
what was done, in the event of a discrepancy between labo-
ratories, or when requested to retest in another laboratory. 
The basic methodology should be reported, along with the 
assay sensitivity. For sequencing assays, each exon sequenced 
should be listed; for targeted mutation assays, each mutation 
targeted should be listed. Standard language regarding FDA 
oversight of laboratory-developed tests should be used, as 
appropriate.
The same overall principles apply to ALK reports, with 
a few distinctions. The results section should also include 
the number of cells analyzed, and the number and percent-
age of cells with each finding. Proper International System 
for Human Cytogenetic Nomenclature (ISCN) nomencla-
ture may be used but, perhaps even more so than for HGVS 
nomenclature and molecular test results, ISCN nomencla-
ture is difficult for the nonspecialist to understand, and col-
loquial nomenclature is essential for clear communication 
of results.
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Question 13: How Should EGFR and 
ALK Testing Be Validated?
13.1: Expert Consensus Opinion.—EGFR and ALK 
testing validation should follow the same guidelines as for 
other molecular diagnostics and FISH tests.
Technical validation, the set of experiments performed 
in the clinical laboratory to assure that an assay is safe and 
reliable for use in patient care, is required in the United States 
under the Clinical Laboratory Improvement Amendments 
of 1988 (CLIA 88). Although the required procedures differ 
between laboratory-developed tests and FDA-approved com-
mercial assays, all tests must be properly validated before 
introduction into clinical use.233 The CAP has published rec-
ommendations and examples on validation for a variety of 
assays.234–239 This section will focus on specific points in the 
validation that the panel believes are of particular emphasis 
for EGFR and ALK validation.
Validation samples should be of all types that will be 
subjected to testing—frozen, fresh, and fixed specimens 
(including each fixative to be used), as appropriate. However, 
it is not necessary to separately validate identically processed 
tissues of different origins (ie, not necessary to validate sepa-
rately FFPE lung, FFPE lymph node, and FFPE brain).
All relevant mutations or rearrangements that are to be 
reported should be included in the validation set, to whatever 
extent is possible. While some rare EGFR mutations may 
not be obtainable, the common exon 19 deletions, L858R, 
T790M, G719, and exon 20 insertions are required. Similarly, 
ALK-positive cases with split signals and with loss of 5′ sig-
nals should both be included in validation sets. It is not neces-
sary to separately validate each individual mutation in each 
specimen-processing type, although it is recommended that 
each type of mutation (ie, point mutation, deletion, insertion, 
split signal, loss of signal) be assessed in each specimen-pro-
cessing type, if possible. Cell lines may be used, but not to the 
exclusion of clinical specimens except for rare mutations.
Precision studies should assess the reproducibility of 
the entire analytic process, beginning with the pathologist’s 
tumor assessment and enrichment strategies (eg, dissection). 
Operationally, therefore, when validation specimens undergo 
repeated testing on different assay runs, those samples should 
be reexamined by a pathologist and redissected.
Accuracy of results is best assessed by comparison with 
another laboratory performing a properly validated assay. 
Similarly, a new method within a laboratory may be validated 
against a previously validated method in the same laboratory. 
Comparison with clinical history of treatment response is sub-
optimal, but may be used as evidence of true positive mutated 
specimens, in the absence of another accredited laboratory for 
comparison. This should not be an issue in the United States, 
where many CLIA-certified laboratories offer these tests.
Analytic sensitivity of EGFR testing should be assessed 
in DNA from mutated specimens with low tumor content, 
diluted both in water/buffer and in normal DNA, to determine 
tumor cell content, in terms of both absolute cell count and 
tumor percentage, at which accuracy and precision (repro-
ducibility) deteriorate. The need for replicate measurements 
to improve accuracy as tumor content decreases should be 
determined thus. Because of variation in EGFR copy number, 
sensitivity studies should be done with more than 1 specimen, 
and the least sensitive result should be stated as the overall 
test sensitivity. Cell lines are not ideal substitutes for clinical 
specimens, although FFPE cell pellets may be helpful, espe-
cially for mutations that are difficult to obtain. The sensitivity 
for FFPE specimens may differ from that for specimens fixed 
in alcohol or frozen.
Analytic specificity studies should establish criteria 
for distinguishing between true-positive and false-positive 
results. Specificity of EGFR and ALK results should be con-
firmed by clinically validated Sanger sequencing and Abbott 
Vysis ALK Break Apart FISH Probe Kit, respectively, or by 
methods traceable to those methods.
No template controls and very-low-concentration 
wild-type specimens are essential to establish specificity of 
ultrasensitive EGFR mutation detection methods. Artifacts 
associated with ultrasensitive methods should be recorded in 
the standard operating procedure manual.
ALK FISH should be performed on clearly benign tis-
sue as well as ALK wild-type tumors, to help establish the 
minimum frequency of split signals that can be reported as 
true positive, as well as to confirm the 2-probe-diameter mini-
mum distance of signal splitting that can be interpreted as true 
positive.
Question 14: How Should Quality 
Assurance Be Maintained?
14.1:  Expert Consensus Opinion.—Laboratories should 
follow similar quality control and quality assurance 
policies and procedures for EGFR and ALK test-
ing in lung cancers as for other clinical laboratory 
assays. In particular, laboratories performing EGFR 
and ALK testing for TKI therapy should enroll in 
proficiency testing, if available.
While specific requirements and approaches may vary 
somewhat from one country to another, or even between dif-
ferent accrediting organizations within one country (eg, Joint 
Commission versus CAP in the United States), the funda-
mental principles are conserved and retained; tests must be 
properly validated, undergo regular quality control and instru-
ment maintenance, with monitoring of the laboratory envi-
ronment and reagent integrity, be performed by competent 
personnel following clear and informative standard operating 
procedures, with participation in external proficiency testing 
procedures and subject to regular inspections by accrediting 
agencies.
Outside the United States, there are local initiatives 
for EGFR mutation testing in, among others, Germany, 
Austria, France, Italy, Greece, the Netherlands, Spain, and 
Japan.1,125,240–242 In some countries the national pathology soci-
ety has rules stating that participation in ring trials for external 
quality assurance in molecular diagnostics is obligatory. The 
frequency of these assessments varies from once a year (the 
Netherlands, Greece, Italy) to twice a year (Germany).
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In some countries, proficiency testing is performed by 
sending a similar sample (set) simultaneously to the partici-
pating laboratories, which report the results to the organizing 
body. Subsequently, the results are compared and a concor-
dant result is a sign of adequate performance. Currently, there 
are no US regulatory requirements for reporting proficiency 
testing for EGFR and ALK assays, although proficiency test-
ing must be performed and documented, as with all laboratory 
tests. The CAP offers an external proficiency testing program 
for EGFR and KRAS mutation testing, and is developing a 
program for ALK FISH. CLIA regulations require alternative 
assessment schemes as substitutes for mandated successful 
performance on external proficiency testing. When an exter-
nal proficiency testing program is not available, then labora-
tories may organize their own proficiency testing program by 
exchanging specimens with 1 or more other laboratories at 
least twice per year.
In Europe, an initiative for EGFR testing has been 
started in collaboration with the European Molecular Genetics 
Quality Network, European Society of Pathology, European 
Society for Medical Oncology, and European Thoracic 
Oncology Platform, in which 10 specimens (cell lines, neu-
tral buffered formalin fixed for 24 hours and embedded 
in paraffin) are validated by 4 laboratories (Greece, United 
Kingdom, Germany, Italy) and now run in a pilot scheme of 
24 laboratories.125
In regions of the world where sample exchange is not 
available, laboratories may confirm accuracy of their results by 
semiannual clinical chart review of tested patient specimens, 
with the understanding that accurate determination of EGFR 
and ALK status may not be determined exclusively by benefit 
from EGFR TKI therapy, as erlotinib/gefitinib response rates 
for EGFR-mutated lung cancers can be in the 75% to 90% 
range, and the crizotinib response rates are comparable for 
ALK-rearranged lung cancers.243 This may be due to upstream 
or downstream factors that render the EGFR TKI ineffective.
CONClUSIONS: GUIDelINe DeVelOPMeNT IN 
THe eRA OF GeNOMIC MeDICINe
During the past decade, scientific and technologic 
progress in cancer genomics research has accelerated the 
pace of discoveries that can be potentially translated into 
significant clinical advances for patients with major com-
mon cancers. The clinical translation of these discoveries 
drives an ever-increasing need for tumor genotyping, based 
on these newly established relationships between type of tar-
getable gene mutation and response to targeted agents. In the 
case of the present molecular testing guideline for selection 
of lung cancer patients for EGFR and ALK TKIs, the press-
ing need to establish standards and provide recommenda-
tions had to be addressed in the context of the limitations of 
the literature. For many recommendations, especially more 
technical ones, articles reporting controlled studies were few 
or absent. For recommendations shaped by survival data, the 
recent and rapid clinical development of these indications, 
especially that of crizotinib in ALK-rearranged lung cancers, 
meant that relatively limited published data were available 
as compared to previous molecular testing guidelines such 
as the ASCO/CAP Guideline Recommendations for Human 
Epidermal Growth Factor Receptor 2 Testing in Breast 
Cancer.98 In such a rapidly evolving area (and era) of medi-
cal practice, we expect that testing guidelines will increas-
ingly have to be developed on more limited published data, 
integrating expert consensus opinion, with an expectation 
that such guidelines will be updated regularly as more rig-
orous meta-analyses of controlled studies become possible 
over time. Indeed, the present guideline does not encompass 
less prominent but nonetheless important testing areas, for 
instance, for selection of patients for MET-targeted therapies 
(MET amplification or overexpression)244,245 and ERBB2-
targeted therapies (ERBB2 mutations),248,319-322 and more-
over, even as the present guideline was under development, 
new testing indications in lung cancer emerged, notably for 
rearrangements of the ROS and RET genes.205–210 Moreover, 
recent technical innovations, such as “next generation” or 
massively parallel sequencing, afford the potential to detect 
all of these alterations, plus many others, in 1 assay.157,248,249 
Although these technologies are very promising, at the pres-
ent, there are still insufficient published data on the accuracy, 
precision, sensitivity, specificity, TAT, and clinical validity of 
these methods in a clinical laboratory setting. Whereas these 
next-generation sequencing-based methods are currently not 
ready for routine widespread clinical implementation, their 
application to clinical medicine is growing rapidly, and they 
may form the core technology of the next version of these 
guidelines. Nonetheless, many aspects of the current guide-
line are “platform-independent” or “platform-agnostic” and, 
therefore, they should inform the evaluation and implemen-
tation of emerging diagnostic tests for EGFR and ALK status 
based on massively parallel sequencing.
Thus, the challenges for guideline development are 
mounting and include the variety of types of genetic altera-
tions to be tested, the rapidly increasing number of clinically 
relevant cancer genes, the limited published literature and 
testing experience associated with the accelerated regulatory 
approval of targeted drugs, and the special issues created by 
the coapproval of commercial companion diagnostic tests. 
Even as models for guideline development evolve to adapt 
to these new factors and pressures, there remains an ongo-
ing clinical need for such testing guidelines to establish and 
widely disseminate best practices based on systematic and 
critical literature review and broad consensus opinion from 
highly experienced stakeholders.
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